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ABSTRACT
Gene-editing technology, such as CRISPR/Cas9, holds great promise for
the advancement of science and many useful applications technology. This
foundational technology enables modification of the genetic structure of
any livingorganismswithunprecedentedprecision. Yet, in order to enhance
its potential for societal benefit, it is necessary to adapt rules andproduce ad-
equate regulations.This requires an interdisciplinary effort in legal thinking.
Any legislative initiative needs to consider both the benefits and the prob-
lematic aspects of gene editing, from a broader societal and value-based per-
spective.This paper stems from an interdisciplinary research project seeking to
identify and discuss some of the most pressing legal implications of gene-
editing technology and how to address these.
While the questions raised by gene editing are global, laws and regula-
tions are to a great extent bound by national borders. This paper presents
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Law, Harvard Law School, Oxford University Press, and Stanford Law School. This is an Open Access
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a European perspective, written for a global audience, and intends to
contribute to the global debate. The analysis will include brief references
to correspondingUSA rules in order to place these European debates in the
broader international context.
Our legal analysis incorporates interdisciplinary contributes concerning
the scientific state of the art, philosophical thinking regarding the precau-
tionary principle and dual-use issues as well as the importance of commu-
nication, social perception, and public debate. Focusing mainly in the main
regulatory and patent law issues, we will argue that (a) general moratori-
ums and blank prohibitions do a disservice to science and innovation; (b)
it is crucial to carefully consider a complex body of international and Euro-
pean fundamental rights norms applicable to gene editing; (c) these require
furtherdevelopments grounded in consistent andcoherent implementation
and interpretation; (d) legal development should followacritical contextual
approach capable of integrating interdisciplinary contributions and broad
multilevel societal dialog.
KEYWORDS: gene editing, CRISPR/Cas9, patents, regulation, interdisci-
plinary perspectives, ELSI
I. INTRODUCTION
In April 2015, Chinese scientists announced the use of gene-editing technology in hu-
man embryos.1 Chinese laws and regulations did not explicitly control or monitor re-
search concerning modification of the germline of humans.2 Reportedly, the embryos
usedwere unviable and not intended to be implanted.The announcement sparked con-
troversy, igniting strong reactions in the scientific community, and fueled public debate
concerning the regulation of gene-editing technology.This highlighted oncemore that
it is more pressing than ever to debate and make national and international decisions
on how to interpret, adapt, or produce adequate rules and regulations. Given the com-
plexity and the great variety of applications of the technology, this calls for an interdis-
ciplinary effort and the incorporation of interdisciplinarity in legal thinking.
This paper is the result of an interdisciplinary research project conducted by a Euro-
pean group of lawyers, biologists, philosophers, social scientists, and physicists. Taking
into account the international context, we identify and debate some of the perceived
legal and regulatory challenges that scientists, legislators, and society as a whole face in
Europe.
We argue that before society can harness this technology’s potential it is impera-
tive to consider from a broader societal and value-based perspective not only the enor-
mous benefits that gene editing may bring, but also its problematic aspects. Our legal
analysis incorporates contextual elements, based on a legal reflection built upon in-
terdisciplinary contributes such as the scientific state of the art, philosophical analysis
concerning the precautionary principle and the dual-use problem, the importance of
communication, social perception, and public debate.
While the questions raised by gene editing are global, laws and rules are to a
great extent bound by national borders. The present piece is an European perspective
1 Puping Liang et al.,CRISPR/Cas9-Mediated Gene Editing in Human Tripronuclear Zygotes, 6 PROTEIN&CELL
363–72 (2015).
2 Yaojin Peng,TheMorality andEthicsGoverningCRISPR–Cas9 Patents in China, 34NAT. BIOTECHNOL. 616–18
(2016).
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written for a global audience, intended as a research contribute to the global debate
on how to regulate the potential uses and applications of gene-editing technology.The
analysis will include brief references to correspondingUSA rules in order to place these
European debates in the broader international context.
Gene-editing technology, such asCRISPR/Cas9,3 holds the potential to guide sem-
inal discoveries within basic science and open a Pandora’s box of practical applications.
This foundational technology provides tools that enable researcherswith a basic knowl-
edge of biochemistry andmolecular biology tomodify with improved precision the ge-
netic structure of any living organism. Possible applications include plant, microbial,
animal, and human genetic intervention.
In plant biology, CRISPR/Cas9 technology represents a precise and timewise un-
precedented efficient tool for gene editing and an economically feasible route to engi-
neered plant variants with desired characteristics, such as improved nutritive value or
disease resistance, high content of health-promoting compounds, or offeringmore effi-
cient startingmaterial for productionofbiofuels orhighvalue compounds.Light-driven
production systemsbasedon engineeredphotosynthetic cells andusing carbondioxide
as the sole carbon source offer the opportunity to facilitate themove toward a biobased
society.4 In the microbial field, improvement of existing fermentation-based platforms
anddevelopmentof entire newones is envisioned for productionof bulk andfine chem-
icals including bioethanol, jet fuels,5 natural sweeteners,6 and health-promoting anti-
oxidants such as resveratrol.7
Within the animal area, development of sterile male malaria mosquitoes8 and new
gene-drive technology9 provide new, effective tools in the fight against malaria. Gene
editing can be used to combat schistosomiasis and other snail-borne diseases,10 and
to increase growth rate and body mass in animal and poultry husbandry, as well as in
aquaculture.
In humans, this technologymay form the basis for new approaches to eradicating or
preventing severe genetic diseases such asHuntington’s disease, sickle cell anemia, and
many other illnesses. In theory, it could equally be used in humans in order to modify,
introduce, or improve traits, features, and performance levels.
3 CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats. Cas9 stands for CRISPR-
associated protein 9.
4 Plant Power—The Ultimate Way to Go Green: Birger Lindberg Møller at TEDxCopenhagen 2012, YouTube
(2017), https://www.youtube.com/watch?v=6oiWJOTydWAa (last accessed Apr. 27, 2017); Lærke
Mu¨nter Lassen et al., Redirecting Photosynthetic Electron Flow into Light-Driven Synthesis of Alternative Prod-
ucts Including High-Value Bioactive Natural Compounds, 3 ACS SYNTH. BIOL. 1–12 (2014).
5 Pauli Kallio et al., Renewable Jet Fuel, 26 CURR. OPIN. BIOTECHNOL. 50–5 (2014).
6 Varanuj Chatsudthipong &Chatchai Muanprasat, Stevioside and Related Compounds:Therapeutic Benefits Be-
yond Sweetness, 121 PHARMACOL. & THER. 41–54 (2009); Recombinant Production of Steviol Glycosides,
PCT/US2011/038967. 02.06.2011.; KimOlsson et al.,Microbial Production of Next-Generation Stevia Sweet-
eners, 15 MICROB. CELL FACT. 207 (2016).
7 MartaG.Novelle et al.,Resveratrol Supplementation:Where AreWeNow andWhere ShouldWeGo? 21AGEING
RES. REV. 1–15 (2015).
8 JamesEGentile, SamuelRund&GregoryRMadey,Modelling Sterile InsectTechnique toControl the Population
of Anopheles gambiae, 14 MALARIA J. 92 (2015).
9 Andrew Hammond et al., A CRISPR-Cas9 Gene Drive System Targeting Female Reproduction in the Malaria
Mosquito Vector Anopheles gambiae, 34 NAT. BIOTECHNOL. 78–83 (2015).
10 Sara Reardon,Welcome to the CRISPR Zoo, 531 NATURE 160–63 (2016).
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However, before harnessing the potential of gene-editing technology society has
to address broad and complex ethical and societal challenges. Potential uses of gene-
editing technology that are particularly controversial include changes in the human
germline passed on to future generations; human enhancement; genetic modification
of wild insect and other animal populations; andmodified crop plants for use as human
food and livestock fodder.
Around the globe, scientists, small and large-scale industries, interest organizations,
artists, and policymakers are engaging in a vigorous and value-laden debate. Literature
and cinematographic works fuel fears and high hopes. The mass media contribute to
construction of extremist narratives concerning emerging technology.Major industrial
players are portrayed as focusingon short-termeconomic gain, beingover optimistic on
benefits, blind to possible negative effects, andwith little interest in engaging in an open
debate with other relevant stakeholders. Popular culture is rife with alarmism, misper-
ceptions, and dystopian futuristic scenarios that find their way into the policy debate
via the discourse of the technology’s opponents. On the other side of the spectrum, we
find hyperoptimistic views of possibilities and minimization of risks communicated by
proponents of immediate and unlimited use of the technology.
In between these radical positions, scientists worry over the possibility of a negative
public perception toward GMOs resulting in a spillover effect into synthetic biology
and genetic editing. This is partly due to the very nature of gene-editing technology,
which makes it particularly difficult to establish distinctions and clear boundaries in
both scientific terms and in the eyes of the public. Issues of traceability, containment,
and distinctions between natural and ‘unnatural’ also challenge previous definitions,
regulatory frameworks, and case law.11
Controversies abound and legal battles are inevitable. Examples can be found in
ongoing patent litigation and patentability debates, as well as in calls for technologi-
cal moratoria and research limitation. In 2011, a group of non-governmental organi-
zations released a report with specific regulatory recommendations on new biologi-
cal techniques for building and remaking organisms for research and commercial uses
ranging frommedicines to biofuels. Synthetic biology is described as ‘an extreme form
of genetic engineering’ and a moratorium on its use was advocated.12 Recent appli-
cations in plant sciences to produce vanillin in yeast carried out at the University of
Copenhagen13 stimulated a fierce international debate concerning both the well-being
of indigenous vanilla farmers and labeling the vanillin produced as natural.14 As for
gene editing in humans, the aforementioned announcement of gene editing in unviable
11 Gene Editing in Legal Limbo in Europe, 542 NATURE 392, 392 (2017).
12 The International Civil Society Working Group on Synthetic Biology, The Potential Impacts of Syn-
thetic Biology on the Conservation & Sustainable Use of Biodiversity: A Submission to the Conven-
tion on Biological Diversity’s Subsidiary Body on Scientific, Technical & Technological Advice, (2011),
http://www.etcgroup.org/sites/www.etcgroup.org/files/publication/pdf file/cbdsynbiocsosubm.pdf (last
accessedMay 10, 2015).
13 Nethaji J. Gallage et al., Vanillin Formation From Ferulic Acid in Vanilla planifolia is Catalysed by a Single En-
zyme, 5 NAT. COMM. 4037 (2014). Esben H. Hansen et al., De Novo Biosynthesis of Vanillin in Fission Yeast
(Schizosaccharomyces pombe) and Baker’s Yeast (Saccharomyces cerevisiae), 75 APPL. & ENVIRON. MICROBIOL.
2765–74 (2009).
14 § 6 (2) Biotech Directive. Cf. Gina Kolata, A Proposal to Modify Plants Gives GMO Debate New Life,
THE NEW YORK TIMES, 2017, http://www.nytimes.com/2015/05/29/a-proposal-to-modify-plants-gives-
gmo-debate-new-life.html? r=0 (last accessed June 5, 2015).
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embryos15 prompted a torrent of criticism, fueled fears of a eugenic future, and re-
ignited the human enhancement debate. Two distinct groups of high-profile scientists
called for a moratorium on editing germline genomes with CRISPR/Cas9 and zinc-
finger nucleases.16
Editing of the human germline is prohibited in several jurisdictions and heavily
regulated in others.17 In the EU, the patentability of such technology is also subject
to restrictions under the Biotechnology Directive.18 Recently, in the USA a National
Academies Report concluded that ‘heritable germline genome editing trials must be ap-
proached with caution, but caution does not mean they must be prohibited’.19 Given
the potential for life-saving treatment, cost-effective manufacture of pharmacological
substances, and sustainability gains, current approaches should be revisited and de-
bated in light of legal, ethical, social, and life science arguments.
These anecdotes illustrate very clearly how new applications of gene editing present
several complex, multifaceted challenges, to both the scientific and medical communi-
ties, in addition to political decision makers and indeed to society as a whole. Against
that complex background, this paper provides an European interdisciplinary perspec-
tive on the challenges, threats, and opportunities associated with gene editing. Debates
on regulating emerging technology risks becoming excessively polarized and often fo-
cusing more on the technologies potential, dystopic or utopic uses, rather than on it
actual scientific reality. In Section II, this paper will begin with a scientific preface pre-
senting the current scientific state of the art and its limitations and available technology.
This section will also address the perceived regulatory and ethical hurdles faced by sci-
entists. Ethical interrogations are often central to public policy choices in life science
innovation. Section III presents two central ethical issues often present in public policy
arguments concerning the regulation of gene editing technology: dual-use issues and
the precautionary principle.These have also been recurrent topics in European debates
concerning emerging technology. Incorporating the previous analysis, Section IV pro-
ceeds to the core of this paper a legal analysis and interpretation of existing laws and
regulations applicable to gene editing. Two aspects are considered: first international,
European, and EU human rights law establishing fundamental principles and as we ar-
gue constituting an umbrella framework for regulation and second the regulatory role
15 See Puping Liang et al., CRISPR/Cas9-Mediated Gene Editing in Human Tripronuclear Zygotes, 6 PROTEIN &
CELL 363–72 (2015); Xiangjin Kang et al., Introducing Precise GeneticModifications into Human 3PNEmbryos
by CRISPR/Cas-Mediated Genome Editing, 33 J. ASSIST. REPROD.& GENET. 581–88 (2016).
16 Edward Lanphier et al.,Don’t Edit theHumanGermLine, 519NATURE 410–11 (2015);David Baltimore et al.,
A Prudent Path Forward for Genomic Engineering and Germline GeneModification, 348 SCIENCE 36–38 (2015).
17 As for Europe, see for example the restriction imposed by article 13, Council of Europe Convention for the
Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and
Medicine: Convention on Human Rights and Biomedicine (CETS n.o164), [hereinafter Oviedo Conven-
tion], entered into force onDec. 1, 1999.Only 28 countries have ratified (out of 47member states). Absences
include, eg the EU as an institution, Germany, Ireland, Italy, The Netherlands, Poland, Sweden, UK, Israel,
and the Russian federation.
18 See with further references: Timo Minssen & Ana Nordberg,The Impact of ‘Broccoli II’ and ‘Tomatoes II’ on
European Patents in Conventional Breeding, GMOs, and Synthetic Biology: The Grand Finale of a Juicy Patents
Tale? 34BIOTECHNOL. L. REP. 81–98 (2015); cf.AnaNordberg&TimoMinssen,A ‘Ray ofHope’ for European
StemCell Patents or ‘Out of the Smog into theFog’?AnAnalysis ofRecentEuropeanCaseLawandHow itCompares
to the US, 47 IIC – INT’L REV. INTELL. PROP. & COMPETITION L. 138–77 (2016).
19 NATIONALACADEMYOFSCIENCEANDNATIONALACADEMYOFMEDICINE,REPORT:HUMANGENOMEEDITING:
SCIENCE, ETHICS, AND GOVERNANCE 145 (TheNational Academies Press 2017).
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exercised by patent. Although patent normswere not developedwith themain purpose
of regulating technology, these have a de facto regulatory role. In particular in Europe,
where exceptions to patentability are directly linked and based in a legislative logic of
inserting public policy mechanisms in patent law. Furthermore, in the quest to provide
a balanced level of incentive to innovation and technologic development case-law de-
velopment on patentability and patent eligibility rules and requirements contains an
element of public policy capable of influencing science and technology development.
Likewise, patent ownership disputes create narratives and current of public opinion,
which find their way into the political discourse.The patent wars for theCRISPR-CAs9
invention will be analysed from a legal view point in Section IV, and also from a public
communication perspective in SectionV. In this section, we debate the pitfalls and nec-
essary considerations involved in public communication of the technology to support
robust sociotechnical development.The final sections of this paper will use these argu-
ments and debates as a background for discussion and suggestions as to how to proceed
(Section VI) and our final remarks (Section VII).
II. SCIENCE AND TECHNOLOGY
The interlinked global challenges related to climate change, population increase,migra-
tion, food insecurity, environmental degradation, depletion of fossil fuels, economic
inequality, and financial vulnerability are well known and their impacts documented.
It is necessary to develop disruptive innovative approaches offering new industries a
clear competitive edge in the global market. Successful transition to and realization
of a knowledge-based bioeconomy relies heavily upon the ability to turn these chal-
lenges into vehicles for sustainable growth, and is dependent on increased focus on in-
terdisciplinary research addressing the global challenges that humanity is facing and
providing science-based solutions to alleviate problems envisioned. Researchers and
industries need to collaborate in developing new and innovative products from renew-
able resources and novel green technology that possess transformative power, that are
within the economic realm, and that benefit consumers. In parallel, health care sys-
tems face the urgent challenge of newly arising infectious diseases and growing lifestyle-
based diseases. Development of new antibiotics, effective and non-toxic treatments of
cancers, and personal medicines tailored to the individual genetic profile will gain im-
pact. In this realm, the availability of technology-enabling targeted andefficient genome
editing offers numerous opportunities.
II.A.The State of the Art
In microbes and plants, a brute force type of genome editing has been available to ob-
tain genetic variation based on radiation or chemical mutagenesis. These procedures
introduce changes in the DNA of organisms. Changes may range from single muta-
tions in a few or multiple genes to multiple mutations in numerous genes to dele-
tion of entire segments of DNA, or to major DNA relocations and rearrangements
within the genome of the organism. In all cases, the changes in DNA introduced by
the irradiation and chemical mutagenesis approaches occur at random positions in the
host genome. The effort to select a specific single mutant which has gained a desired
property among the large collection of mutants obtained is time consuming and labor
intensive. In addition, to gain the full benefit of an identified desired mutation, a series
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of back-crosses to the wild-type organism are required to remove other simultaneously
introduced mutations with negative effects. Nevertheless, these procedures have been
important because they have enabled introductionof changes thatwouldnot be achiev-
able by classic crossings between related species or between a high yielding species and
a wild relative. The parallel development of molecular-based high-throughput screens
such as TILLING (Targeting Induced Local Lesions in Genomes) has made it easier
to identify mutations in a specific gene.20
Initial brute force approaches have been superseded by more efficient targeted mu-
tagenesis approaches. Within recent decades, researchers including microbiologists,
plant biologists, and human biologists have made major progress using the tools of
molecular biology to refine methods of gene editing. The main objective has been
to introduce a desired mutation in a specific gene in a selected genome without si-
multaneous introduction of numerous side mutations. These series of approaches
developed have been dependent on sequence-specific nucleases such as meganucle-
ases, zinc-finger nucleases, and TAL effector nucleases.21 These nucleases contain a
modular DNA-binding domain engineered to recognize the specific target DNA se-
quence as well as a nuclease domain cleaving the target DNA. Although outperform-
ing the classic non-targeted mutagenesis approaches, these methodologies were not
straightforward to apply, being based on construction of large proteins, and suffered
from context-dependent lack of specificity. However, these pioneering studies have
spurred continued efforts to develop simpler andmore rapid gene-editing systemswith
improved target specificity.Themost recent result of these efforts is theCRISPR/Cas9
system.16 In this gene-editing system, the Cas9 endonuclease is targeted to a spe-
cific location in the genome guided by a short-guide RNA sequence derived from the
CRISPR array and a second helper RNA. These RNAs may be fused into a single
RNA molecule.22 This mode of recognition greatly simplifies system design. A recent
publication by Barrangou and Horvath23 provides an overview of the development of
the CRISPR-Cas technology over the last decade. Videos illustrating the key steps in
CRISPR/Cas-based gene editing are available on the internet.24
In nature, the CRISPR/Cas9 system is part of a memory-based immune defense
system found throughout the kingdom of prokaryotes including bacteria and archaeal
species enabling them to counteract infection fromviruses.25 Different types of systems
20 Cecilia K. Blomstedt et al., A Combined Biochemical Screen and TILLING Approach Identifies Mutations in
Sorghum bicolor L. Moench Resulting in Acyanogenic Forage Production, 10 PLANT BIOTECHNOL. J. 54–66
(2011).
21 PatrickD.Hsu, Eric S. Lander&FengZhang,Development andApplications of CRISPR-Cas9 for Genome Engi-
neering, 157CELL 1262–78 (2014);Khaoula Belhaj et al.,Editing PlantGenomeswithCRISPR/Cas9, 32CURR.
OPIN. BIOTECHNOL. 76–84 (2015); Samuel H. Sternberg et al., Adaptation in CRISPR-Cas Systems, 61 MOL.
CELL 797–808 (2016); Matthias Heidenreich & Feng Zhang, Applications of CRISPR–Cas Systems in Neuro-
science, 17 NAT. REV. NEUROSCI. 36–44 (2015).
22 Martin Jinek et al.,AProgrammableDual-RNA-GuidedDNAEndonuclease in Adaptive Bacterial Immunity, 337
SCIENCE 816–21 (2012).
23 Rodolphe Barrangou & Philippe Horvath, A Decade of Discovery: CRISPR Functions and Applications, 2 NAT.
MICROBIOL. 17092 (2017).
24 See for example https://www.youtube.com/watch?v=MrpcBvlrpig (last accessed Sept. 12, 2017).
25 Marie-Laurence Lemay, Philippe Horvath & Sylvain Moineau, The CRISPR-Cas App Goes Viral, 37 CURR.
OPIN. MICROBIOL. 103–09 (2017).
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are known.26 ACRISPR locus typically harbors a number of CRISPR-associated genes
(Cas genes) encoding endonucleases as well as the CRISPR signature domain com-
posed of a series of direct repeat sequences interspaced with short spacer sequences
derived from viral genomes. When a virus species attacks a bacterium or archaea, the
Cas endonuclease dissects a small piece of the viral DNA and integrates this piece of
DNA at a specific position in the DNA of the prokaryote designated as the CRISPR se-
quence array.TheCRISPR sequence array is thus composed of a series of variable viral
spacer sequences each separated by direct repeats and orchestrated by the endonucle-
ase activity of the Cas enzyme. Upon each new viral attack, a new spacer derived from
the virus genome sequence is integrated into the CRISPR sequence array. The region
of the viral genome fromwhich the spacer is derived is designated the protospacer and
is characterized by possessing an adjacent motif which serves to direct the Cas9 en-
donuclease to cleave the viral DNA. If the protospacer adjacent motif is mutated, virus
resistance is lost.
The CRISPR signature sequence is transcribed as a single RNA and then processed
by different pathways into shorter RNAs each harboring individual viral spacer se-
quences. In theCas9 system, hybridization to an additional non-coding transactivating
RNA is required to direct the Cas9 endoproteinase to recognize and specifically de-
grade the complementary sequences present in the infecting virus. A virus is not able to
successfully infect bacteria or archaea which carry a signature CRISPR sequence corre-
sponding to a sequence in the viral genomes.
The CRISPR/Cas9 system can be transferred to eukaryotic cells including mam-
malian cells and has been redesigned to facilitate targeted gene editing in eukaryotes.
From the description above, it is apparent that the CRISPR/Cas9 system requires
three components: theCas9 endonuclease, a non-coding transactivatingRNA, andma-
ture CRISPR RNA. To facilitate the experimental protocols for gene editing using the
CRISPR/Cas9 system, the twoRNAsmaybe combined into a single-guideRNA.27 For
gene editing of a eukaryotic organism, thematureCRISPRRNA sequencemay now be
substituted with a short sequence derived from the target gene. Multiple guide RNA
sequences may be used to target several genes in the same transformation event or to
target other effectors, eg transcription factors to alter gene expression.28 In case a gene
encoding an inactive Cas9 nuclease is introduced, a wide array ofmodifications of gene
regulation in the host cell may be introduced in a partly programmable manner.29
With this CRISPR/Cas9 technology, the DNA of the host organism is cut at a site
in the genome predefined by its sequence. At this location, a single base mutation,
gene deletions, replacement of a mutated disease-causing gene, insertion of a differ-
ent isoform of the gene from the same species or new genes from different organisms
may be introduced. In contrast to classic mutation breeding, by using CRISPR/Cas9
26 Toma´sˇ Cˇerma´k et al. A Multipurpose Toolkit to Enable Advanced Genome Engineering in Plants, 29 PLANT &
CELL 1196–217 (2017).
27 Jinek et al., supra note 22, at 816–21.
28 Cˇerma´k et al., supra note 26; J. A. Aznar-Moreno & T. P. Durrett, Simultaneous Targeting of Multiple Gene
Homeologs to Alter Seed Oil Production in Camelina sativa, 58 PLANT CELL PHYSIOL. 1260–7 (2017).
29 Antonia A. Dominguez, Wendell A. Lim& Lei S. Qi, Beyond Editing: Repurposing CRISPR–Cas9 for Precision
Genome Regulation and Interrogation, 17 NAT. REV. MOL. CELL BIOL. 5–15 (2015).
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technology the site at which themutation is introducedmay be controlled upfront and
the type of mutation introduced may also be designed.30
The Cas9 encoding gene is of bacterial origin and does not occur naturally in plants
and animals including humans. When the desired change in the DNA of the host or-
ganism has been accomplished using CRISPR/Cas9 methodology, the gene encoding
the Cas9 enzyme may be completely removed. Following genome editing, sequencing
of the entire genome can be carried out to ascertain that the changes introduced are
as originally planned and that no other changes have resulted during the process. This
requires sequencing of the genome before and after editing. Genome sequencing tech-
nology is constantly being improved, and within the next decade such a quality check
will be feasible economically as well as timewise.31 When CRISPR/Cas9 gene-editing
technology is being used to insert a gene from a foreign organism into a host cell, the
resulting organism should be considered as genetically engineered and subject to the
regulations for genetically engineered organisms. When CRISPR/Cas9 technology is
used to introducemutations to correct amalfunctioning gene in the host organism and
the CRISPR/Cas9 gene cassette is subsequently removed, no foreign genes have been
inserted. Proponents of CRISPR/Cas9 technology would therefore argue that the re-
sulting organism is not classified as genetically engineered because the same mutation
could have been obtained by classic mutagenesis-based breeding.32
Proponents of newer and much more precise gene-editing technology would argue
that the organisms obtained would constitute no additional challenges to the environ-
ment in comparison to those already present in nature.However, the impact of genome
editing is determined by the nature of the specific trait being modified or introduced.
Microorganisms subjected to gene editing and grown on an industrial scale in environ-
mentally contained fermenters would not give rise to descendants in nature as long as
unintended spillage is avoided. Gene-edited crop plants would be grown in the fields,
and traits introduced would be transferred to descendants and to cross-pollinating-
related species. In humans, traits introduced in egg cells would transfer to subsequent
generations. Thorough risk analyses are thus required in spite of benefits envisioned
related to improved bioproduction in yeast or photosynthetic cells, more robust crop
plants, or elimination of serious genetically inherited human diseases from a family.
In other cases, non-awareness of the type of associated risks demands thorough risk
analysis.
Recent technological developments within gene editing open up new opportunities
in all branches of life science.Theuse ofCRISPR/Cas9 in synthetic biology approaches
offers the opportunity to design systems with new desired properties spanning from
in vitro systems and cell factories to microorganisms, plants and animals including hu-
mans. It is also important that theCRISPR/Cas9 system affords functional analysis of a
selected gene in its natural environment. In basic science, this offers a unique approach
to assigning functions to specific genes and regulatory elements. The importance of
30 Xuan Liu et al.,Application of CRISPR/Cas9 in Plant Biology, 7 ACTA PHARM. SIN. B 292–302 (2017); C.C.M.
van de Wiel et al., New Traits in Crops Produced by Genome Editing Techniques Based on Deletions, 11 PLANT
BIOTECHNOL. REP. 1–8 (2017).
31 Armin Scheben et al., Towards CRISPR/Cas Crops—Bringing Together Genomics and Genome Editing, NEW
PHYTOL. (2017) doi: 10.1111/nph.14702.
32 Id.
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precise gene editing relates to the fact that the genomesof eukaryotic organisms contain
tens of millions of DNA bases the sequence of which encodes several thousand genes.
The ability to knock out the function of a specific gene, to replace a mutated gene, or
to insert a new gene at a desired position in the genome has been a major challenge.
CRISPR/Cas9 technology offers precise editing of genetic modules and controlling el-
ements. It offers new opportunities to edit, modulate, or interrupt the function of genes
in their endogenous environment of most organisms. In basic science, this offers a new
approach for functional characterization of genes.33
Previously, molecular technology for therapeutic treatment of genetic disorders in
humans has not been available due to unacceptable risks. CRISPR/Cas9 offers the op-
portunity to simultaneously perturb several genes enabling studies of additive effects
of polygenetic disorders in humans and thus offers an opportunity to cure polygenic
diseases. Diseases caused by ‘loss-of-function genes’ as is the case in cystic fibrosis and
sickle-cell anemia could be cured.
In plants, theCRISPR/Cas9 systemoffers the possibility to exchange a specificmal-
functioning gene or a disease-causing mutation with a wild-type gene. Such homolo-
gous recombination only occurs at very low frequency (<1%) using classic genetic en-
gineering. Increased resistance to pests, improved tolerance to drought, flooding, and
saline soils may offer higher yields in parallel with increased plasticity and adaptation
to environmental stresses based on optimized content of specialized metabolites. The
breeding of more robust plants that provide stable and high yields in spite of adverse
growth conditions exacerbated by climate change is a major global challenge which
must be dealt with to avoid a global shortage of food.34
II.B.OpenQuestions and ScientificChallenges
CRISPR/Cas9 technology clearly represents a major advantage with respect to gene
editing of microorganisms, plants, and animals including mammals. The technology is
a key tool for scientists who want to study biological systems at the molecular level of-
fering quick access to knockout mutants, site-specific mutations, and transfer of genes
between organisms that cannot be crossed. But, like any technology, CRISPR/Cas9
technology also has its limits. It is not 100% specific, meaning that DNA sequences
outside the planned target site may be cleaved by Cas9 endonuclease. In other situ-
ations, the target sequence may bind to Cas9 without being cleaved, which in most
cases will cause an altered gene expression pattern.35 Whole genome control sequenc-
ing will reveal information about off-target cleavage of genes but cannot be used to
monitor changes in expression pattern.36 One uncertainty related to current reports
on successful gene editing using the CRISPR/Cas9 system in plants is the stable heri-
tability of the trait introduced.37 The editing process requires introduction of the gene
encoding Cas9 endonuclease and guide RNA with a sequence complementary to the
DNA sequence of the target gene. If the CRISPR/Cas9 construct is not removed, it is
33 Holger Puchta,Applying CRISPR/Cas forGenome Engineering in Plants: the Best is Yet to Come, 36CURR.OPIN.
PLANT BIOL. 1–8 (2017).
34 Puchta, supra note 33, at 1–8; Agustin Zso¨go¨n et al.,Genome Editing As a Tool to Achieve the Crop Ideotype and
De NovoDomestication of Wild Relatives: Case Study in Tomato, 256 PLANT SCI. 120–30 (2017).
35 Dominguez et al., supra note 29.
36 Scheben et al., supra note 31.
37 Jinek et al., supra note 22, at 816–21.
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difficult to determine whether the genetic change introduced was indeed inherited by
the next generation or whether themutationwas produced once again.The presence of
theCRISPR/Cas9 construct for several generationswould also be expected to increase
the risk of off-target changes. Strategies for insolating the CRISPR/Cas9 construct are
available but far fromalways used.38 Inmicroorganisms andplants, off-targetmutations
introduced by CRISPR/Cas9 technology may be eliminated by back-crossings.
Lack of 100% specificity is obviously of major concern regarding use of the technol-
ogy in human clinical applications introducing permanent changes in the genome and
offspring, although most off-target aberrations may not have any importance. In this
context, it is important to remember that, on average, each human receives approxi-
mately 60 newmutations in their genome from the parents.39 Some of thesemutations
constitute a positive driving force in evolution,while othersmay be neutral or disabling.
The rapid adoption of CRISPR/Cas9 technology by the global research community
and companies is basedon the relative ease of this procedure compared toprevious pro-
tocols for gene editing and the improved set ofmolecular biology tools available.Open-
source guidelines and easy access to constructs, e.g. from Addgene,40 further speed up
implementation of the CRISPR/Cas9 system in a range of different microorganisms,
plants, and animals including mammals.The speed of implementation is a challenge to
attempts to achieve a balanced discussion of the positive and negative aspects of this
potent gene-editing technology. Likewise, with the easy and largely open distribution
of gene constructs and molecular kits, the scientific community, legal authorities, and
individual researchers have few opportunities to prevent individuals or groups of peo-
ple from engaging in uses of gene constructs and protocols without prior regulatory
approval. Such experimentation may take place in multiple private settings. Citizen-
scientists, researchers, and well-established DIY communities share the responsibility
to use technology responsibly.
II.C. Communication, Ethics, and Law in the Lab
In public opinion, issues of multidrug-resistant microbes are often considered coupled
with and arising from the introduction of genetically engineered plants harboring genes
conferring antibiotic resistance. From a scientific perspective, this association is not
correct. However, it demonstrates the great challenge and social responsibility borne
by the research community to communicate and engage in upfront discussion. Some
researchers would argue that changes in biological food chains and in microbial, plant,
andwild animal communities caused by climate change are of farmore importance and
impact than those causedby introductionof genetically engineered species.41 Although
38 Id.; Xiuhua Gao et al., An Effective Strategy for Reliably Isolating Heritable and Cas9 -Free Arabidopsis Mu-
tants Generated by CRISPR/Cas9-Mediated Genome Editing, 171 PLANT PHYSIOL. 1794–800 (2016); Eszter
Kapusi et al., Heritable Genomic Fragment Deletions and Small Indels in the Putative ENGase Gene Induced by
CRISPR/Cas9 in Barley, 8 FRONT. PLANT SCI. 540 (2017); YanfeiMao, Jose RamonBotella & Jian-Kang Zhu,
Heritability of Targeted Gene Modifications Induced by Plant-Optimized CRISPR Systems, 74 CELL MOL. LIFE
SCI. 1075–93 (2017).
39 Reed A. Cartwright et al., A Family-Based Probabilistic Method for Capturing De Novo Mutations from High-
Throughput Short-Read Sequencing Data, 11 STAT. APPL. GENET. &MOL. BIOL. 1544–6115, 1713 (2012).
40 See Addgene.org (2017), https://www.addgene.org (last accessedMay 17, 2017).
41 See United States Environmental Protection Agency (2017), https://19january2017snapshot.epa.gov/
climatechange .html (last accessedMay 17, 2017).
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this is correct, public mistrust toward implementation of new technology needs to be
addressed through serious studies and monitoring, but not by delaying use of promis-
ing technology and our efforts to move toward a biobased society that would mitigate
some of the negative effects of climate change. The recent open later signed by 110
Nobel Prize winners regarding genetically engineered Golden Rice does not embrace
or invite opponents of the technology to have a say. In the debate about gene editing,
an argument often presented by natural scientists is that ‘it is the end product which
matters’.42 All the evidence suggests that this is not the way to discuss the issue, for it
is crucial to take into account the concerns of stakeholders and the general public in
setting policy priorities.
Different applications generate diverse risks and benefits. It is important to base as-
sessments on a clear scientific understanding of different production systems, their re-
lated benefits, and disadvantages, incorporating ethical reasoning inmethodologies. At
a time when humanity needs to move toward a biobased society, it is more than ever
important that the methodologies behind biological production are understood and
their implementation in terms of producing medicinal compounds, flavors, and other
food ingredients is adequately debated upfront. These discussions need to be based
on inputs from all stakeholders, thus including the general public, politicians, indus-
try, and scientists from a broad range of fields and disciplines. From a life science sci-
entist perspective, it seems clear that challenges need to be taken seriously and prop-
erly addressed in order to ensure that production systems are optimizedwith respect to
overall reduced risks,minimized environmental impact, and commercial viability. Such
public policy debates require engaging multiple stakeholders and the interdisciplinary
academic community. Only through close interdisciplinary dialog and broad societal
involvement, we can achieve the vital development of a sound legal policy at the service
of the global community.
III. ETHICAL PERSPECTIVES ON REGULATION AND UNCERTAINTIES
The recent development of CRISPR/Cas9 as a superior tool for genome editing in
plants, animals, and humans raises profound ethical issues and poses challenging ques-
tions to stakeholders including scientists and regulators. In this section, we will reflect
on some of the ethical issues that have become pressing in the context of research using
CRISPR/Cas9 technology and some of its potential applications. To begin with, it will
be useful to distinguish two lines of ethical discussion regarding gene editing. On the
onehand, onemight discusswhether scientists should evenbe allowed tomake changes
to living systems at the genetic level. The very idea of genetically engineering naturally
evolved life may seem morally abhorrent, whatever benefits we envisage to come out
of it. This is not the ethical outlook that we will adopt in this paper. On another ap-
proach, presented in this paper, the central question is not whether the technology is
intrinsically morally wrong, but how to use it in a morally justified way. Under what
conditions should using it be allowed?What sort of applicationsmight it be used to de-
velop?What regulatory initiatives should be taken? In other words, CRISPR/Cas9 is a
42 Detlef Weigel,The End Product is What Matters (2016), https://www.mpg.de/10444274/genome-editing-
breeding-better-crops (last accessed May 17, 2017); Felix Wolter & Holger Puchta, Knocking Out Consumer
Concerns and Regulator’s Rules: Efficient Use of CRISPR/Cas Ribonucleoprotein Complexes for Genome Editing
in Cereals, 18 GENOME BIOL. 43 (2017).
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tool that may be used in many different contexts, by many different people, for many
different purposes. And it is fast becoming a stalemate of genetics research everywhere.
Therefore, one thorny issue concerns how to regulate the use of CRISPR/cas9 (and
future gene-editing technology) given the fundamental uncertainty about the possible
consequences of having this tool in our hands. In this section, we will comment on two
themes concerning decisionmaking about the use of gene editing. First, we will discuss
whether a precautionary approach to gene editing should guide regulation. Second, we
consider the dual-use aspect of gene-editing technology. An underlying debate, which
has received considerable attention, concerns the possibility of the gene editing of hu-
mans (and human embryos) for scientific, therapeutic, and enhancement purposes.
This debate involves profound questions about specific applications of the technology
and about the very distinction between therapy and enhancement.43 However, in the
context of this paper, we limit ourselves to considering how to make decisions about
such specific applications of the technology.
III.A. Precaution
The advent of CRISPR/Cas9 technology makes it pertinent to consider how to reach
the right decisions about what to do in terms of regulating, funding, and developing the
technology and the research and applications that it may enable. Whatever specific ap-
plication of CRISPR/Cas9 one might envisage, important questions are likely to arise
about possible risks to human health and the environment. Aswithmany other fields of
technology, therewill also be issues concerning social justice.Whowill benefit fromuse
of the technology?Matters of securitywill also loom large.A tool such asCRISPR/Cas9
could be used for nefarious purposes, and we have to consider this when regulating
its use. Finally, an important issue concerns who has the authority to make decisions
about what changes can be made to which organisms using gene-editing technology.
Is it morally permissible or perhaps required for one generation of humans to make
changes to the genetic profile of their descendants through germline genetic therapy or
enhancement, or both?
The current debate about the ethics of gene editing was set off by the use of the
CRISPR/Cas9 technology on human embryos. The ensuing suggestion to establish a
moratoriumon some uses of CRISPR/Cas9 is an example of taking a precautionary ap-
proach to a certain domain of application of the technology.This is arguably justified by
the fact that the consequences of going ahead remain highly uncertain. While it is gen-
erally agreed that the consequences of the arrival of CRISPR/Cas9 are unclear, there is
less consensus on how to regulate its use and development. Should it be permitted to
use CRISPR/Cas9 on viable but discarded human embryos to study questions about
43 On the legal concept of enhancement, seeNordberg infranote148; on the difficulties of establishing andusing
such distinction in legal practice, see Ana Nordberg,Human Enhancement from Ethical Interrogations to Legal
(Un)certainty, in INTELLECTUALPROPERTYPERSPECTIVESONTHEREGULATIONOFNEWTECHNOLOGIES (Tana
Pistorius ed., 2018).
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human development,44 or to develop gene therapy and/or enhancement?45 Should we
use CRISPR/Cas9 technology to make cows without horns and engineer mosquitoes
to resist the parasite that causes malaria? Progress in genetics and fine-tuning gene-
editing techniques will only raise more questions like this. What is certain is that deci-
sionsmust bemade in situations characterized by uncertainty.Whenuncertaintymeets
biotechnology, there is often pressure on decision makers to invoke the Precautionary
Principle.
A relatively clear and representative formulationof thePrecautionaryPrinciple is this:
The Precautionary Principle asserts that parties should take measures to protect public
health and the environment, even in the absence of clear, scientific evidence of harm. It
provides for two conditions. First, in the face of scientific uncertainties, parties should
refrain from actions that might harm the environment, and, second, that the burden of
proof for assuring the safety of an action falls on those who propose it.’46
The Precautionary Principle has gained traction during the last 50 years.47 It is invoked
in the Kyoto Protocol,48 while the EuropeanUnion allows countries to invoke the Pre-
cautionary Principle when making decisions about a risky activity.49 Debate about the
use of CRISPR/cas9 in some domain or other is likely to revolve around questions
about whether a precautionary approach should inform regulation. In the debate about
GMOs, many European countries have enacted restrictions on genetically modified
crops and food on the basis of the ‘Precautionary Principle’.50 Influential organizations
such as Greenpeace, Friends of the Earth, and ETC group consistently cite the Precau-
tionary Principle as a justification for strict regulation ormoratoria on development and
use of biotechnology.The principle also governs international legal arrangements such
as the United Nations Biosafety Protocol.51
Given its status as an enabling technology and its wide range of applications, we find
that there is no single question about whether gene editing per se should be allowed or
banned. Nevertheless, making decisions about the use of gene editing on a case-to-case
basis will still amount to making decisions about the regulation of a technology that
44 Haroon Siddique, British Researchers Get Green Light to Genetically Modify Human Embryos. THE GUARDIAN
(2017), https://www.theguardian.com/science/2016/feb/01/human-embryo-genetic-modify-regulator-
green-light-research (last accessedMay 8, 2017).
45 Brendan P. Foht, Gene Editing: New Technology, Old Moral Questions, THE NEW ATLANTIS (2016), http://
www.thenewatlantis.com/publications/gene-editing-new-technology-old-moral-questions (last accessed
May 8, 2017).
46 Ken Geiser, Establishing a General Duty of Precaution in Environmental Protection Policies in the United States:
A proposal, in PROTECTING PUBLIC HEALTH AND THE ENVIRONMENT: IMPLEMENTING THE PRECAUTIONARY
PRINCIPLE (Carolyn Raffensperger & Joel Tickner eds., 1999).
47 For a series of examples supposed to show why absence of scientific certainty should not be required for pre-
caution, see PAUL HARREMOES ET AL. (EDS), THE PRECAUTIONARY PRINCIPLE IN THE 20TH CENTURY: LATE
LESSONS FROM EARLYWARNINGS (2002).
48 Kyoto Protocol to the United Nations Framework Convention on Climate Change, FCCC/CP/L.7/Add.1,
Kyoto (1997).
49 European Commission (2000). Communication from the Commission on the Precautionary Principle.
http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex:52000DC0001 (last accessedMay21, 2017).
50 Andrew Porterfield, Is the Precautionary Principle Guiding Law or a Political Notion?, GENETIC LITERACY
PROJECT (2016), https://www.geneticliteracyproject.org/2016/06/23/precautionary-principle-guiding-
law-political-notion/ (last accessedMay 21, 2017).
51 Geiser, supra note 46.
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comes with the possibility of significant and perhaps very great harm to humans and
the environment. This seems to support applying the Precautionary Principle and sig-
nificantly restricting the use of gene editing.However, there are important reasons to be
critical of the Precautionary Principle as a guide to making decisions under conditions
of uncertainty. Consider the time when genetic engineering was in its infancy and re-
searchers were beginning to develop recombinant DNAmethods. In a letter published
by a group of experts in Science52 in the wake of a meeting organized by the National
Academy of Sciences in the USA, the authors recommended a moratorium on all re-
search on recombinant DNA studies on the basis of the possibility that there might be
risks.The famousAsilomar conference followed the year after, focusingonwhat sort of re-
combinantDNA research could be safely undertaken.Commenting on the precaution-
ary approach initially taken to recombinant DNA,Watson suggests that that approach
may have been morally misguided: ‘There were desperately sick people out there, peo-
ple with cancer or cystic fibrosis—what gave us the right to deny them perhaps their
only hope?’53
What Watson is criticizing here is neglect of the costs of not doing something de-
spite the risks of doing it. In its most simple formulation, the Precautionary Principle
may seem to ignore the costs of not continuing a line of research and development.We
find that while a broadly precautionary approach to regulation of gene editing is justi-
fied, it is important that the Precautionary Principle is interpreted in a way that avoids a
disproportionate (and potentially incoherent) focus on the possible harm. According
to the analysis we favor, a precautionary approach should be guided by an understand-
ing of the Precautionary Principle along the lines suggested by Steel.54 In this account
precautions will not be justified if they are as likely to lead to harm of the same or bigger
magnitude as the activity with respect to which they are proposed.55 We thus suggest
an alternative to traditional cost–benefit analysis.Whether or not to adopt cost–benefit
analysis in situations of uncertainty is a complex question. Moreover, assessing this
question in any detail is beyond the scope of this paper. However, a significant worry
should be noted about cost–benefit analysis, namely that it ‘requires an ability to make
quantitative predictions of the costs and benefits of alternative policy options’.56This in
turn suggests that cost–benefit analysis may in situations of scientific uncertainty ‘lead
to an inability to decide whether the benefits of a regulation would be greater or less
than the costs’.57
III.B.TheDual-Use Problem
A technology may be characterized as a dual-use technology when it can be used for
both good and bad purposes.58 It is characteristic of dual-use technology that the risk
52 Paul Berg et al., Potential Biohazards of Recombinant DNAMolecules, 185 SCIENCE 303, 303 (1974).
53 JAMES D. WATSON, DNA: THE SECRET OF LIFE 98 (2013).
54 DANIEL STEEL, PHILOSOPHY ANDTHE PRECAUTIONARY PRINCIPLE: SCIENCE, EVIDENCE, AND ENVIRONMENTAL
POLICY (2014).
55 Id. chapter 2.
56 Id. at 23.
57 Id. at 23.
58 For an in-depth discussion of the dual use dilemma, see Seumas Miller & Michael J. Selgelid, Ethical and
Philosophical Consideration of the Dual-use Dilemma in the Biological Sciences, 13 SCI. & ENG. ETHICS 523–80
(2007).
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is sufficiently high that it can be used in bad ways. Furthermore, dual-use technology
tends to generate a problem because increasing the possibility of production of ben-
efits will tend to increase the possibility of misuses of the technology. Thus, dual use
of a technology gives rise to questions about how to make decisions about regulating
the development and use of dual-use technology. Gene editing is arguably a dual-use
technology.The features that make it powerful, such as the possibility of making highly
targeted changes to genomes, is the reason why it holds great promise, but also why it
raises great concerns.
The dual-use aspect of gene editing means that it raises a series of ethically signifi-
cant decisions that ‘revolve around balancing scientific freedom, governance, risk and
security’.59 These decisions will confront not just national governments but also indi-
vidual scientists, who must decide what research to conduct and to publish; research
institutions, which must decide, among other considerations, how to regulate research
within their confines, how to educate their researchers, and what laboratory security
measures should be in place; funding organizations, which must decide how consid-
erations of dual-use research and technology are incorporated in their application and
reviewprocesses; professional societies, whichmustmake decisions about the develop-
ment, promulgation, and/or enforcement of codes of conduct and education; editors
and publishers, whomustmake decisions on review and publication of potentially dan-
gerous papers; and international organizations, whichmustmake decisions concerning
relevant global policy.60
Summing up, CRISPR/Cas9 and future gene-editing technology can potentially
produce enormous benefits to humans, but the uncertainty about possible harm that
may result from large-scale gene editing means that a precautionary approach is advis-
able to policy decisions that respect a proportionality constraint on acceptable precau-
tions. Furthermore, the dual-use nature of gene editing entails that a range of initia-
tives should be considered concerning its application.These include research oversight
mechanisms, policies for funding agencies, policies for journal publishers, institutional
and professional codes of conduct and ethics, and awareness-raising and educational
initiatives for a range of audiences.
III.C. Law and Ethics in EmergingTechnologies
Law and morality constitute two separate, but intersecting normative systems. The
sphere of personal andgroupbeliefs, conceptions, and feelings onwhat constitutes good
or bad conducts is necessarily broader than the sphere of state enforcedmandatory con-
ducts. Law requires normative decisions balancing, and sometimes choosing between
different ethical perspectives. Understanding the need to include ethical thinking in
legal development efforts, in the following sectionwe analyse existing norms, their pos-
sible interpretation(s), and applicability to gene-editing technology. The topics here
debated will be revisited and inform the analysis of the human rights framework (Sec-
tion IV.A), specific regulations (Section IV.B), and public policy norms in patent law
with regulatory effect (Section IV.C).
59 FILIPPA LENTZOS, DUAL USE IN BIOLOGY AND BIOMEDICINE 14 (2015).
60 Id.
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IV. LAW AND GENE EDITING
Regulation of emerging technology can be pursued through norms in different fields
of law either directly or indirectly. The same is also valid as far as gene editing is con-
cerned.This section focuses on two types of interrelated legal issues with practical im-
plications for the future direction anddevelopment of the technology.First, wewill con-
sider selected questions concerning regulation of the technology in its strict sense, i.e.
establishing rules concerning to what extent, how, by whom, and under what condi-
tions gene editing should be allowed. In this sense, this section considers the underly-
ing legal framework based on international and European fundamental rights, and also
examines specific examples of rules and regulations. Second, we will examine issues of
patentability of gene editing and the current disputes on ownership of the CRISPR-
CAS9 technology.
Aswewill argue, both these questions are interconnected andhave broader practical
repercussions beyond legal theoretical debates. Patent lawhas an indirect regulatory ef-
fect and is in this sense connected with regulatory efforts as such. Being a type of incen-
tive and reward structure, patent law’s intended function is to provide well-balanced
incentives and rewards to ensure that investment in innovation is sufficiently attrac-
tive so that a steady flow of beneficial new products and processes are developed and
made available to society. In this sense, the application of an exception frompatentabil-
ity denies the benefit of that incentive to a specific invention.However, patent eligibility
norms also carry a broader symbolic regulatory effect,which extends the reachof refusal
of a patent grant beyond the invention examined and even beyond the patent system.
For example, a refusal to grant on morality grounds might result in a chain reaction of
overall reduction in the various types of incentives to innovate and invest in the areas
of research concerned.
The application of such norms to gene-editing patent applications is a de facto pow-
erful policy tool.Moreover, patent ownership disputes can also have a chilling effect on
investment and delaymarket introduction of socially beneficial innovations.Due to the
importance of the technology and the potential ‘blockage effect’ of ongoing patent lit-
igation, alternative private law mechanisms are emerging, and will here be considered.
These are intended tominimize such effects and allow the use and further development
of the technology regardless of the outcome of patent wars.
IV.A.HumanRights: anUmbrella Framework for Regulation
International treaties and conventions generate obligations for signatory states as to
their reception and integration in the corresponding national legal orders. National
law must respect and be applied in a manner consistent with those obligations. In this
sense, human rights norms provide guidance and serve as platforms for harmonization
of national legislative and adjudicative developments and form the basis of an inter-
national umbrella framework for regulation.The United Nations Educational, Scientific
andCulturalOrganization (UNESCO)has issued three declarations relevant to genetic
technology.
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The Universal Declaration on the Human Genome and Human Rights61 declared the
humangenomeas a symbolic ‘heritage of humanity’.62 Article 24mandatesUNESCO’s
International Bioethics Committee (IBC) to ‘give advice concerning the follow-up of
thisDeclaration, inparticular regarding the identificationof practices that couldbe con-
trary to human dignity, such as germ-line interventions’.63 It does not as such establish
a prohibition, but indicates that germline intervention is highly controversial. A central
point of the debate resides in the dual-use issue. On one side is the fear of eugenic prac-
tices, while on the other prohibiting access to therapeutic intervention collides with the
right to health. The choice of the verbal form ‘could be’ indicates lack of international
consensus and that determining whether germline intervention might offend human
dignity is not a closed debate. As the IBC recognized recently, rapid developments in
genetics require continuous reflection and re-interpretation of these principles.64 In
that sense, the International Declaration on Human Genetic Data65 re-affirms a broad
construction of the concept of personality. Respect for diversity, non-discrimination,
non-stigmatization, and autonomy are recognized consequences of respecting human
dignity.66 Declaring the human genome to be a heritage of humanity should not en-
tail reducing humanity to its biological dimension.The UN recognizes that ‘a person’s
identity should not be reduced to genetic characteristics, since it involves complex ed-
ucational, environmental and personal factors and emotional, social, spiritual, and cul-
tural bonds with others and implies a dimension of freedom’.67 It acknowledges the
continuous evolution of the human genome and epigenetics phenomena. The human
genome evolves by nature and is in constant mutation. Genetic potential is ‘expressed
differently according to each individual’s natural and social environment, including the
individual’s state of health, living conditions, nutrition and education’.68
TheUniversal Declaration on Bioethics andHuman Rights69 was intended ‘to provide
a universal framework of principles and procedures’ to guide states, corporations, and
other public or private actors in the formulation of legislation, policies, rules, and ac-
tions in the field of bioethics.70 It establishes the primacy of individual interests over
the interests of science and society,71 consecrating a principle of maximizing bene-
fit and minimizing harm to affected individuals.72 Autonomy, informed consent and
61 Universal Declaration on the Human Genome and Human Rights, adopted by the UNESCOGeneral Con-
ference on Nov. 11, 1997 and endorsed by the United Nations General Assembly, 53rd session, resolution
AIRES/53/152, Dec. 9, 1998 [hereinafter Human Genome Declaration].
62 Article 1, Human Genome Declaration.
63 Article 24, Human Genome Declaration.
64 Report of the IBC on Updating Its Reflection on the Human Genome and Human Rights, UNESCO,
SHS/YES/IBC-22/15/2REV.2 (Paris, Oct. 2, 2015), at 127–8.
65 Article 3, International Declaration on Human Genetic Data, adopted by the UNESCO General Conference
on Oct. 16, 2003 [hereinafter Genetic Data Declaration)].
66 Article 6, HumanGenome declaration; Article 7, GeneticDataDeclaration; Article 11, BioethicsDeclaration
(see infra note 70).
67 Article 3, Genetic Data Declaration.
68 Article 3, Human Genome Declaration.
69 Universal Declaration on Bioethics and Human Rights, adopted by the UNESCOGeneral Conference, Oct.
19, 2005 [hereinafter Bioethics Declaration].
70 Article 2, Bioethics Declaration.
71 Article 3, Bioethics Declaration.
72 Article 4, Bioethics Declaration.
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privacy are also principles mentioned and developed.73 Non-discrimination, justice,
social responsibility, and benefit sharing are declared collective goals of humanity, to
be pursued both by states and by private law actors. Protection of future generations
from ‘the impact of life sciences’, including the impact on their genetic constitution,
is also established as a goal,74 as well as protection of the environment, the biosphere,
and biodiversity.75 Concerning gene editing, the primacy of individual interest is an
interesting principle. It allows argument as to the inapplicability of prohibitive regu-
lations in the interest of individual basic rights such as health, personal beliefs, and
autonomy. The fact that the declaration is also intended to guide the actions of cor-
porations and other non-state actors (public or private) is extremely important. It
is a first step in establishing international patterns of conduct and responsibility in-
dependently of national implementation or in cases where jurisdiction is difficult to
establish.
Recently, the IBC released an updated Report on the Human Genome and Human
Rights,76 recommending a moratorium on genome editing of the human germline.
The report cites safety and ethical concerns as justification,77 and issues final rec-
ommendations. First, it affirms the importance of global responsibility and gover-
nance concerning scientific and technological advances in genomics.78 Governments
and a broad range of stakeholders are invited to join forces to avoid letting the
law of supply and demand determine what is or is not acceptable. It also advocates
shared global standard setting and regulation,79 and the importance of involving the
scientific and bioethics community in global debate. Perhaps more controversially,
the report proclaims that ‘the United Nations [. . . ] should be responsible for mak-
ing fundamental normative decisions’ and that the precautionary principle should
be respected and guide decisions.80 Finally, the report states that ‘the difference be-
tween medical and non-medical use of the new technology remains crucial’. Enhance-
ment techniques should respect human rights and dignity, and obey the precaution-
ary principle. Health protection and health care applications, ‘for instance through
precision and personalized medicine, should be considered as content of the fun-
damental right of every human being to enjoy the highest attainable standard of
health’.81
Historically, domestic legislators and adjudicators have transposed and interpreted
UN human rights norms and principles with considerable variation. Further regional
international legal sources and each country’s constitution/basic laws create an addi-
tional background to specific technological regulation.
73 Articles 5 to 9, Bioethics Declaration.
74 Article 16, Bioethics Declaration.
75 Article 17, Bioethics Declaration.
76 UNESCO, Report of the IBC onUpdating Its Reflection on theHumanGenome andHumanRights (2015),
http://unesdoc.unesco.org/images/0023/002332/233258E.pdf (last accessedMay 17, 2017).
77 Id. at 118.
78 Id. at 115.
79 Id. at 116.
80 Id. at 117.
81 Id. at 122.
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The Council of Europe Convention on Biomedicine82 addresses genetic modification
in Article 13, stating that:
An intervention seeking to modify the human genome may only be undertaken for pre-
ventive, diagnostic or therapeutic purposes andonly if its aim is not to introduce anymod-
ification in the genome of any descendants.
At first sight, this norm contains an absolute prohibition of all non-therapeutic inter-
vention, including therapeutic intervention affecting future generations. However, the
wording of the convention, in particular the expression ‘and only if the aim is not to
introduce any modification in the genome of any descendants’may support a different
reading. It could also be interpreted as allowing intervention directed at medical pur-
poses even if this may entail a modification in somatic cells passed on to descendants.
Thiswould be the case of a genetic interventiondestined to correct amutation, prevent-
ing or irradiating a severe genetically transmittable condition.The direct aim would be
therapeutic, with eventual modification or improvement of future generations in that
family a collateral effect. Acceptance would depend on weighting the medical benefits
against the risks of the procedure, and considering the available therapeutic alternatives
for the individual.The explanatory report to theOviedoConvention,83 which has inter-
pretative value,84 stresses that the primary goal and general interpretative guiding prin-
ciple of the convention is to ‘protect the dignity and identity of all human beings’,85 un-
derstood as protecting the biological and genetic identity of the species 86and inspired
by theprincipleof theprimacyof thehumanbeing.87 Arguably, this principle is honored
insofar as the gene-editing objective is to prevent or correct geneticmutationswhich by
themselves are a threat to the integrity and future of human identity.88 The drafters of
the convention did not enjoy the benefit of current scientific knowledge, which affords
envisioning potential therapeutic applications.The drafters were aware of this fact, de-
bated the possibility for creating exception, and concluded that such was premature
and thus consistently stressed the need for Article 13 to be reviewed after a certain pe-
riod of time to avoid precluding future gene therapy.89 The elements of interpretation
of international treaties mentioned in Articles 31 and 32 of the Vienna Convention90
support the use of a less literal interpretative approach. Later advances in science and
82 Oviedo Convention, supra note 17.
83 Council of Europe, Explanatory Report to the Convention for the protection of Human Rights and Dignity
of the Human Being with regard to the Application of Biology andMedicine: Convention on Human Rights
and Biomedicine 71–73; 89–92 (1997).
84 Id., ¶ 90.
85 Article 1, Oviedo Convention.
86 Article 2, Oviedo Convention.
87 Explanatory Report, supra note 83, at 22.
88 See Explanatory Report, supra at note 83, at 92, stating that ‘the article does not rule out interventions for
a somatic purpose which might have unwanted side-effects on the germ cell line’, and thus distinguishing
between aim and result of a genetic intervention.
89 Council of Europe, Preparatory Works on the Convention for the protection of Human Rights and Dignity
of the Human Being with regard to the Application of Biology andMedicine: Convention on Human Rights
and Biomedicine 63–68 (2000).
90 Vienna Convention on the Law of Treaties, May 23, 1969, United Nations, Treaty Series, vol. 1155, at 331.
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society offer new perspectives to legal interpretation if the relevance of the literal and
historic element is tempered with a dynamic legal interpretation.
The EU Charter of Fundamental Rights includes ‘third-generation’ fundamental
rights relevant in the field of bioethics.91The charter is addressed to the institutions and
bodies of the EU and national authorities when implementing EU law. Outside these
premises, protection of fundamental rights is guaranteed under national constitutional
norms and traditions ofmember states and the international conventions they have rat-
ified. Article 3 consecrates a personal right to respect for physical and mental integrity,
including in particular in the fields of medicine and biology, ‘the prohibition of eugenic
practices, in particular those aiming at the selection of persons’ and ‘the prohibition of
the reproductive cloning of human beings’.92 Article 3 should be read in conjunction
withArticle 35 establishing ‘the right of access to preventive health care and the right to
benefit from medical treatment under the conditions established by national laws and
practices’. As such, there is no direct prohibition of germline modifications.The treaty
merely prohibits eugenics practices, while preventive health care is expressly included
under the right to health. The distinction between eugenics and preventive medicine
has to be framed under specific EU regulatory framework, and developed in national
norms.
The international human rights principles and norms here explored address issues
such as protection of human genetic identity, biodiversity, and environmental protec-
tion. Genetic intervention raises moral objections on several grounds. One of the ma-
jor arguments points to the moral inadmissibility and biological dangers of attempts to
modify human nature. Defense of the biological integrity of the species or the common
genetic heritage of humanity has been transposed from the field of theology and philos-
ophy and entered the international human rights arena. The departure point has been
a static vision of human biology and distinctions between ‘natural’ and ‘technological’.
Counterintuitively, this distinction is difficult to establish in precise scientific terms. As
recentlymentioned in aNationalAcademiesReport, ‘the humangenome is not entirely
‘human’, as it includes Neanderthal and Denisovan DNA. [. . . ] Nor does it exist in any
single, static state. [. . . ]There is no single human genome shared by all of humanity’.93
Furthermore, since germline modifications are only transmitted to descendants, detri-
mental population scale effects are unlikely and would take many generations.
Concerning gene editing of animals and plants, either for laboratory use, industrial
production purposes, or release in the environment, the technology may raise ethical
issues concerning the ethical treatment of animals; conflict with the values of preser-
vation of biodiversity and ‘natural’ ecosystems; and raise human rights concerns con-
nected with the right to health. This is due to perceptions of potential for health risks
associatedwith introduction of edited organisms in the food chain and development of
dangerous streams of bacteria and viruses.
This fundamental rights framework forms the background to regulation of science.
In the next section, we consider the existing rules regulating scientific activities in the
91 Charter of Fundamental Rights of theEuropeanUnion (2000/C364/01),OJC364/1 [hereinafter EUChar-
ter].
92 Article 3 (2), EU Charter.
93 National Academies, supra note 19, at 94–5.
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USA, the EU, and the UK, questioning whether these need to be adapted in order to
address gene-editing-specific characteristics and possibilities.
IV.B. Applying Existing Regulations toGene Editing
The rapid progress in gene-editing technology has left legislators and regulators around
theworld trying tofindout how, or if at all, to regulate these advances and their resulting
applications.Aswithmanyother fields of technology, the applications of gene editing in
plants andmedicine are in the spotlight of the enfolding debates.The debates concern-
ing gene editing have landedon topof unsettled debates inEurope. Areas of technology
regulationwere interpretation of rules is subject to heated legal and societal arguments.
In this section, we have selected two important areas of regulatory action to focus our
analysis. First, we will address the question of the legal characterization of gene edited
plants and the possible applicability of rules concerning genetic modified organisms.
Second, we will briefly consider the use of gene-editing technology in a medical and
veterinary setting.
IV.B.a. Gene-Edited Plants GMO2.0 or Something Else?
Much of the criticism of GMOs, and much of the regulation developed 20–30 years
ago, focusedon transgenics inwhich geneticmaterial fromunrelated species is added to
create new traits in a plant or animal.However, newer breeding techniques (NBT)offer
scientists an easier way to do cisgenic breeding. Put simply, these techniques involve
no ‘foreign’ DNA and thus allow the development of new plant and animal varieties.94
The resulting challenge to current legislation can be described as follows:NBTs such as
CRISPR/Cas9, TALENs, and ZFN do not fit neatly into the GMO definitions crafted
by the various regulatory agencies around the world. Its proponents say gene editing is
similar tomutagenesis, which is not regulated (hundreds ofmutagenized crops are sold
as organic), but faster and more precise.The regulatory process remains fluid.
The need for new regulation covering gene-editing technology in the plant sciences
is particularly debated and evident in the European Union. Administrative authorities
in some EU countries do not consider gene-edited plants to fall under the GMO defi-
nition. For example, the Swedish Board of Agriculture (Jordbruksverket), upon request
from research groups and in two separate decisions, has stated that in their interpre-
tation the GMO legal definition does not encompass plants in which the genome has
been edited using the CRISPR-Cas9 technology.95 In France, in a case opposing farm-
ers’ organizations and environmentalist NGO’s to the French Government, a refer-
ral on the matter is currently pending before the CJEU.96 The referral is expected to
clarify the concept of GMO contained in Directives 2001/18/EC97 and 2002/53/EC,
94 See How are Governments Regulating CRISPR and New Breeding Technologies (NBTs)? GENETIC LITERACY
PROJECT, https://gmo.geneticliteracyproject.org/FAQ/how-are-governments-regulating-crispr-and-new-
breeding-technologies-nbts/ (last accessed Jan. 10, 2017).
95 Decisions available (in Swedish) http://www.umu.se/digitalAssets/171/171718 beslut-umea.pdf, and
http://www.umu.se/digitalAssets/171/171719 beslut-uppsala.pdf (last accessedMay 23, 2017).
96 Request for a preliminary ruling (France) lodged, Oct. 17, 2016 (CJEUCase C528/16).
97 Directive 2001/18/EC of the European Parliament and of the Council of Mar. 12, 2001 on the deliberate
release into the environment of genetically modified organisms (OJ 2001 L 106, at 1).
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and whether uses of gene editing technology can be subsumed to such legal defeni-
tiosn.98
Thematter is also debated in other jurisdictions. In April 2016, the US Department
of Agriculture (USDA) decided that it would not regulate a mushroom and a new
type of corn genetically modified with the gene-editing tool CRISPR/Cas9, making
them the first CRISPR-edited crops to be approved by the US government. According
to the agency’s Animal and Plant Health Inspection Service, these crops—and about
30 other plants they have reviewed—do not qualify as something the agency must
regulate (once a croppassesUSDA reviews, itmay still undergo voluntary reviewby the
USFood andDrugAdministration).99 Biotechnology critics in theUSAhave therefore
calledNBTs ‘hiddenGMOs’ and examples of ‘extreme engineering’, and are pushing to
regulate them under a general GMO umbrella, while biotechnology supporters assert
that regulating them as GMOs would inhibit innovation.100
Hence, it can be said that both current EU Directives and corresponding US laws
do not sufficiently embrace the new interface between genetic engineering and con-
ventional breeding. Although Directive 2001/18/EC encompasses both process- and
product-related stipulations, it is commonly interpreted as a strictly process-based
piece of legislation.101 Since these new techniques are closer to conventional breed-
ing than common genetic engineering, many European commentators argue, like their
US colleagues, that relevant regulations should be phrased and interpreted with more
focus on the resulting product, rather than the process, and that legal guidance on how
to apply ‘the decade-old legislation is urgently needed’.102
Since scientists and companies typically operate internationally and the
development of regulation on gene editing and NBT is facing several hurdles
and inconsistencies on a global level, one study has compared current EU legislation
with existing frameworks in other countries and discussed ideas for an alternative regu-
latory system.103 The most recent version of that study, published in June 2015, found
that the next few years will be defining for the regulatory status of NBTs in countries
outside the EU. In that regard, the study emphasized that ‘several countries are in
varying stages of reviewing the science behind NBTs and their regulatory status, it is
clear that most countries are waiting for other countries or international organizations
to take a position; the EU plays an important role in this waiting game’.The reluctance
of several countries to discuss these topics is linked to political and economic issues.
Since NBTs are virtually untraceable, allowing their use may result in overall de facto
exportation bans to countries with more restrictive regulations. Therefore, the matter
should be debated on a global level by initiatives governing international trade, such as
98 Council Directive 2002/53/EC of June 13, 2002 on the common catalog of varieties of agricultural plant
species (OJ 2002 L 193, at 1).
99 Id.
100 Id. See also Heidi Ledford,Gene-Editing Surges as US Rethinks Regulations, 532 NATURE 158–9 (2016).
101 Thorben Sprink et al.,RegulatoryHurdles for Genome Editing: Process- vs. Product-Based Approaches inDifferent
Regulatory Contexts, 35 PLANT CELL REP. 1493–506 (2016).
102 Id.
103 Schuttelaar & Partners,The Regulatory Status of New Breeding Techniques in Countries Outside the European
Union (2015), http://www.nbtplatform.org/background-documents/rep-regulatory-status-of-nbts-oustide-
the-eu-june-2015.pdf (last accessed Jan. 10, 2017).
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the World Trade Organization.104 Finally, it is noteworthy that NBTs also challenge
the interplay between the systems for plant variety protection and patents (see below in
Section IV.D.d).
IV.B.b. Medical and Veterinary Applications
In the area of medical applications in humans, gene-editing technology also poses
an enormous challenge to existing regulations throughout the world. Gene edit-
ing offers unprecedented opportunities for preventive medicine, affording the
possibility to correct genetic mutations and eradicate congenital disease.105 Eventu-
ally gene-editing technology will reach a safe level that permits clinical applications. In
that event countries considering allowing suchpreventivemedicine interventionwould
have to consider the need to form a global consensus ‘because thinking about germline
gene modification involves ethical, social, and evolutionary considerations for all of
humankind’.106
For example, the recent announcement of gene editing in unviable embryos107 has
prompted a torrent of criticism, fueled fears of eugenic futures, and re-ignited the hu-
man enhancement debate. As mentioned before, two distinct groups of high-profile
scientists have called for a moratorium on editing germline genomes, arguing that re-
searchwhich produces heritable edits to the human genomemust not proceed until the
risks are better understood.108 Similarly, the European Group on Ethics in Science and
NewTechnologies (EGE) issued a Statement on Gene Editing emphasizing that for ‘some
members of the EGE, human germline gene modification for reproductive purposes
cannot be ethically justified’, and that they therefore ‘call for upholding the prohibition
that reflects, among others, Article 3 of the EU Charter; because of the blurring lines
between basic and applied research, some also call for a moratorium on any basic re-
search involving human germline gene modification until the regulatory framework is
adjusted to the new possibilities’.109 However, the statement then also points out that
for ‘othermembers of the EGE, theremay be positions worth consideringwhichwould
justify continued research’. Due to the diversity of views, they then call for a broad pub-
lic debate and urge the EU Commission to request a EGE opinion on ‘the inextricably
linked ethical, scientific and regulatory issues pertaining to germline and somatic cell
gene modification’.110
This view is also shared by a recent study, which further notes—as with NBTs—an
enormous worldwide diversity of attitudes and very different legislation on genetic
technology in humans, such as germline genetic modification, preimplantation genetic
diagnosis, somatic gene therapy, embryonic stem cell research, research cloning, and
reproductive cloning.111 The authors emphasize that public acceptance may change
104 Id. at 46.
105 MotokoAraki&Tetsuya Ishii, International Regulatory Landscape and Integration of CorrectiveGenomeEditing
Into In Vitro Fertilization, 12 REPROD. BIOL. & ENDOCRINOL. 108 (2014).
106 Id. at 10.
107 Liang et al., supra note 1.
108 Lanphier et al., supra note 16; Baltimore et al., supra note 16.
109 European Group on Ethics in Science and New Technologies, Statement on Gene Editing,
https://ec.europa.eu/research/ege/pdf/gene editing ege statement.pdf (last accessed Feb. 6, 2017).
110 Id.
111 R. Isasi, E. Kleiderman & B. M. Knoppers, Editing Policy to Fit the Genome?, 351 SCIENCE 337–39 (2016).
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as the benefits of genome editing emerge for disease prevention and that the collec-
tive sum of individual decisions could constitute a de facto policy.112 However, the au-
thors admonish that ‘the task of adopting policy guidance for the acceptability (if at all)
of germline interventions is more than just editing policy to fit individual genomes or
circumstances’.113
Conversely, in the USA the above mentioned recent National Academies Report
recommends that clinical trials using heritable germline genome editing should be
permitted, and that regulatory approval requirements should encompass absence of
reasonable alternative; prevention of a serious disease or condition; and credible data
on safety and efficiency.114
Clearly, to address these concerns requires a thorough review of regulatory frame-
works. In this context, attention should be given to the changing patterns of use of tech-
nology, since ‘applying normative systems only to traditional hierarchical social struc-
tureswill increasinglyoverlook significantnumbersof relevant actors and thatnewways
of engaging users of technology in moral communities may need to be found’.115
In addition to covering gene-editing science as such, regulation will also have to in-
clude changes to regulatory frameworks for approval of medicines and therapies, such
as USA/FDA regulations and EU/EMA regulations. In the USA, the FDA is already
in the process of enacting new regulations,116 and presumably the EU/EMA is also re-
considering the Regulation on AdvancedTherapies117 and other applicable EU legisla-
tion.118 Presently, the EMA has launched an ongoing revision process seeking to adapt
its overarching guideline on medicinal products containing genetically modified cells
to the advances in gene-editing technology.
A new regulation on clinical trials has been enacted,119 interestingly maintaining
without further clarification a broad prohibition for gene therapy clinical trials ‘which
result in modifications to the subject’s germ line genetic identity’,120 in force under the
112 Id. at 339.
113 Id.
114 National Academies, supra note 19, at 145.
115 Nuffield Council on Bioethics, Genome Editing: An Ethical Review (2016), http://nuffieldbioethics.org/
project/genomeediting/ethical-review-published-september-2016 (last accessedMar. 10, 2017) at 119.
116 Sarah Zhang,The FDA Wants to Regulate Gene-Editing That Makes Cows Less Horny, THE ATLANTIC, 2017,
https://www.theatlantic.com/science/archive/2017/01/the-fda-wants-to-regulate-gene-edited-animals-
as-drugs/513686/ (last accessed Feb. 6, 2017).
117 Regulation (EC) No 1394/2007 of the European Parliament and of the Council of Nov. 13,
2007 on Advanced Therapy Medicinal Products and amending Directive 2001/83/EC and Reg-
ulation (EC) No 726/2004, OJ L 324/121, http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?
uri=OJ:L:2007:324:0121:0137:en:PDF (last accessedMay 4, 2017).
118 European Commission, EudraLex - Volume 1 - Pharmaceutical Legislation for Medicinal Products for Hu-
manUse, http://ec.europa.eu/health/documents/eudralex/vol-1 en (last accessedMay 4, 2017); European
Commission, EudraLex - Volume 5 - Pharmaceutical Legislation for Medicinal Products for Veterinary Use,
http://ec.europa.eu/health/documents/eudralex/vol-5 en (last accessedMay 4, 2017).
119 Regulation (EU) No 536/2014 of the European Parliament and of the Council of Apr. 16, 2014 on clini-
cal trials on medical products for human use, and repealing Directive 2001/20/EC.[Regulation on Clinical
Trials].
120 Article 90, Regulation on Clinical Trials. See also recital 75, Regulation on Clinical Trials.
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previous legislation.121 Rules concerning compassionate use (Article 83 of regulation
726/2004/EC) and named patient-basis treatment programs under national law are
also part of this complex regulatory framework and depending on how these will be ap-
plied may offer routes to discrete and progressive use of gene editing in a therapeutic
setting. Other regulations to consider and interpret in light of gene editing include the
tissues and cells directive,122 applicable to the donation, procurement, and testing of
biological samples used as starting materials for genetic interventions.
IV.B.c.The UKApproach
In Europe, the UK regulatory approach has unique features worthy of mention. The
UK has neither ratified nor signed the Oviedo Convention. It has also recently initi-
ated procedures to leave the EU. However, it is a member of the EPO and likely to join
the Unified Patent Court (UPC).123 The UK was also the first country in the world
to authorize mitochondrial replacement, a technique entailing genetic modifications
transmittable to future generations.
TheHuman Fertilisation and Embryology Actwas recently amended to introduce the
possibility for implantation of embryos obtained through the process of mitochondrial
donation. As noted above, the UK became the first country to directly permit implan-
tation of such embryos.The procedure is allowed as a way to avoid severe genetic con-
ditions.124 By replacing the unhealthy mitochondria of the mother with healthy mito-
chondria from a donor, a healthy child can be born with 99.9 per cent of the DNAof its
parents, and 0.1 per cent of the DNA of the donor.The first license to perform the pro-
cedure in the UK has been granted.125 Previously, the technique had been performed
by John Zhang and his team from theNewHope Fertility Center (New York, USA). US
law does not allow mitochondrial transplants. The procedure was performed in Mex-
ico, where it is not directly regulated. A male child was born on April 6, 2016, show-
ing no signs of Leigh syndrome, the mitochondrial transmitted disease carried by the
mother.126
During parliamentary debates, use of words such as genetic modification, editing, or
manipulationwas carefully avoided.Debate focusedmostly on potential benefits in sav-
ing lives and avoiding the pain and suffering associated with severe diseases. However,
the technology does entail modification of the human genome transmittable to future
121 Article 9 (6), Directive 2001/20/EC of the European Parliament and of the Council of Apr. 4, 2001 on the
approximation of the laws, regulations, and administrative provisions of the member states relating to the
implementation of good clinical practice in the conduct of clinical trials on medicinal products for human
use, OJ L 121, 1.5.2001, at 34.
122 Directive 2004/23/EC of the European Parliament and of the Council of Mar. 31, 2004 on setting standards
of quality and safety for thedonation, procurement, testing, processing, preservation, storage, anddistribution
of human tissues and cells (OJ L 102, 7.4.2004, at 48–58).
123 Unified Patent Court, Update on UPC ratifications – UK signals green light (2016), https://www.
unified-patent-court.org/news/update-upc-ratifications-uk-signals-green-light (last accessedMay 4, 2017).
124 Human Fertilisation and Embryology Act 2008 c 22, Section 35A ‘Mitochondrial donation’.
125 Human Fertilization and Embryology Authority, Licence Committee—Minutes (2017), http://
ifqtesting.blob.core.windows.net/umbraco-website/1331/2017-03-09-licence-committee-minutes-
variation-of-licensed-activities-to-include-mitochondria-pronuclear-transfer-pnt-centre-0017.pdf (last
accessedMay 4, 2017).
126 John Zhang et al., First Live Birth UsingHumanOocytes Reconstituted by Spindle Nuclear Transfer forMitochon-
drial DNAMutation Causing Leigh Syndrome, 106 FERTIL. & STERIL. e375–76 (2016).
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generations. Arguments used to allow the procedure can equally apply to therapeutic
uses of gene editing. The issue of whether gene editing should be accepted on a sim-
ilar basis has already been raised,127 and the UK Human Fertilisation and Embryology
Authority has authorized gene-editing research on human embryos.128
IV.C. Patent Issues and their Regulatory Role
Patent rights are an administrative concession granting the right to prevent third parties
frommaking, using, offering for sale, selling, or importing for these purposes a patented
product or a product obtained by the patent process. Grant of a patent also entails the
right to assign the patent, or transfer by succession, and to conclude licensing agree-
ments. A patent does not establish the right to use technology or to place on the mar-
ket products embedding the patent. It does not imply an official stamp ofmoral approval
on technology and its various possible uses. However, patent eligibility rules indirectly
exercise a regulatory function. Patent rights are instrumental to the development of a
given technology.Although alternative incentivemechanisms exist and innovationmay
occur regardless of patent rights, large investments in technological development are
usually dependent on the existence of exclusionary rights. Technology is developing at
a fast pace and industrial actors are keen on developing mechanisms to avoid an even-
tual impasse created by intertwined rights and long litigation. Under this setting, it will
beof importancewhether patents coveringCRIPSR/Cas9 andother gene-editing tech-
nology remain in force and which actors own or obtain licenses to exclusionary rights.
IV.C.a. Patents and theGhost of Eugenic Futures
Slippery slope arguments and debates on human nature are a constant in debates con-
cerning scientific and technology advances in human genetics. In previous parts of
this paper, we analysed general ethical perspectives (Section II) and the human rights
framework constructed to protect the human genome and its legal conceptualization as
heritageof humanity and its preservation as a legal valuewith fundamental right dignity.
In this section, we analyse similar issues and debates from a perspective of interpreta-
tion and application of patent law rules on patentable inventions.
Patent law being a very dynamic field of law is likely to be one of the first legal ar-
eas where ethical compliance of gene editing with the fundamental legal principles and
regulatory norms will be confronted. Patent law is so far themost universal legal incen-
tive to innovation, and in this sense it assumes an indirect policy function, visible in the
inclusion of extra-economic considerations in patentability rules.These considerations
are intended to ensure compliance with ethical values and scientific needs by imposing
restrictions on the patentability of certain inventions, transposing the ethical debate to
patent law.This section explores how European patent eligibility normsmight apply to
gene editing.
127 Progress Educational Trust, From Three-Person IVF to Genome Editing: The Science and Ethics of Engineering
the Embryo, http://www.progress.org.uk/conference2015 (last accessedMay 4, 2017).
128 Authorization was granted to Kathy Niakan, stem cell researcher at the Francis Crick Institute. The goal is
to determine which genes are crucial for healthy cell division, and then use that knowledge to screen em-
bryos, potentially preventing miscarriages and aiding fertility. The embryos concerned cannot be older than
seven days and will not be implanted. See The Francis Crick Institute, HFEA Approval for New ‘Gene Edit-
ing’ Techniques, (2016), https://www.crick.ac.uk/news/science-news/2016/02/01/hfea-decision/ (last ac-
cessedMar. 4, 2017).
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Modifying the germline genetic identity of human beings is expressly excluded from
patentability in Europe.129 This entails that method claims directed at such develop-
ments of gene-editing technology may not be eligible for patent protection. Somatic
cell gene methods in principle will not face such objections. These concern modifica-
tions in somatic cells bymeans of recombinantDNAand only operate in the cells of the
recipient butwill not be carriedon todescendants.Nevertheless, itwill still benecessary
to evaluate such intervention in light of the general broader ‘ordre public’ and moral-
ity patentability exception, since such intervention can also raise ethical concerns. As a
point of legal interpretation, it can be argued that all intervention involving the human
body carries risks and potential (known and unknown) side effects. Objections based
on safety and danger for humanity of unintended side effects or mutations changing
the common human genetic heritage are merely a question of weighting therapeutic ben-
efit against risk, something present in every medical decision (e.g. use of antibiotics or
vaccination).The risks are unknown, but even germline editing will only be carried on
to descendants, making wider population effects a distant scenario. Technology will
continue to develop and might afford the possibility to correct/reverse unwanted off-
target modifications. Insofar as therapeutic applications for severe health conditions
are concerned, no substantial difference exists between the well-established practice of
parental consent to perform conventional therapy or surgery to treat or manage a dis-
ease and the use of gene-editing technology to prevent future generations from ever
developing the disease. In such situations, it can be argued that the (future) individual
has the right to health and access to treatment and hence legal guardians have at least
the right (if not the duty) to procure the best medical treatment available. Parental re-
fusal of treatment is subject to specific regulations and mostly only acceptable under
exceptional circumstances—eg conflict with other fundamental rights—and thus the
same reasoning might be extended by analogy to the use of safe and non-experimental
preventive gene therapy.
Gene editing might also be used outside purely therapeutic situations. The issue of
acceptability of humanenhancementhas for a considerable timebeen theobject of legal
philosophical debates. Rawls argued that ‘the parties want to ensure their descendants
the best genetic endowment’130 arguing that by virtue of the difference principle131
‘greater abilities are a social asset to be used for the common advantage’,132 and con-
cludes that ‘society is to take steps at least to preserve the general level of natural abili-
ties and to prevent the diffusion of serious defects’.133 This line of reasoning would en-
dorse all genetic intervention (including gene editing) as long as such intervention has
the purpose of avoiding serious disease or disability. Naturally, this reasoning implies
a pre-determination of the legal concepts of disease, disability, and therapy. Dworkin
goes further; contending that morality requires society to allow parents to genetically
enhance their children so that they may have broader choices and greater chances of
129 Rule 28(b) EPC implementing Regulations; § 6 (2) (b) Biotechnology Directive.
130 JOHN RAWLS, A THEORY OF JUSTICE 92 (1999).
131 SeeRAWLS , supra note 130, at 65 and JOHN RAWLS & ERIN KELLY, JUSTICE AS FAIRNESS 76 (2001).
132 RAWLS , supra note 130, at 92.
133 See also ALLEN BUCHANAN, FROMCHANCE TOCHOICE 302 (2000), defending the case that genetic enhance-
ments are morally permissible and laudable, and that therapeutic genetic intervention to prevent disabilities
is a moral imperative.
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succeeding in life.134 On the other hand, Fukuyama warns that genetic enhancement
is a threat to liberal democracy due to the possibility that it will alter human nature,
arguing that genetic engineering should be subject to strict regulatory constraints and
its admissibility limited to clearly therapeutic treatments.135 Habermas wrote that such
intervention denies the child the possibility to be revised in adult life by ‘critical reap-
praisal’, denying a person’s ability to be ‘the undivided author of his own life’.136 More
recently, enhancement proponents and transhumanismadepts counterargue that these
objections would equally apply to many parenting practices not generally considered
controversial.137 Some authors defend the right to enhancement and a moral impera-
tive to eradicate disease.138
Modifying the germline genetic identity of human beings is expressly mentioned
as an exclusion from patentability.139 Recitals 38 and 40 of the Biotechnology Direc-
tive express legislative intent ‘to exclude unequivocally from patentability processes
for modifying the germ line genetic identity of human beings’.140 Patent norms do not
make functional distinctions, meaning that the purpose of an intervention—the actual
use claim in the patent application—is immaterial. Under this literal interpretation, all
interventions in germ cells will encounter patentability hurdles, including in the ab-
stract, even thosewith purely therapeutic purposes. Somatic cell interventionwould fall
outside the scope of the specific provision; however, these still require an assessment of
their moral conformity under the general ‘ordre public’ and morality clause.141 As fol-
lows from the European legal tradition, further interpretative elements can, and should
when appropriate, be taken into consideration by adjudicators. Below we consider sys-
temic elements such as the human rights framework and issues of legal coherence.
IV.C.a.i. Patentability andHumanDignity. Interpretationof theBiotechnologyDirective
cannot be blind to theEUCharter and the international human rights treaties signed by
some or all member states. Moreover, these are also relevant to the EPO’s interpreta-
tive praxis. However, because the grant of a patent is independent from administrative
authorizations tomarket products or conductmedical procedures, patentability cannot
be denied simply based on legal prohibition.142This entails that a specific ethical debate
has to be developed within the European patent system for purposes of applicability of
patent eligibility norms.
As mentioned above, a considerable body of international norms has been enacted
with the purpose of protecting ‘human nature’.143 These are problematic because the
concept of human nature is culturally biased and historically relative. It can be un-
derstood in a strict biological sense, but also culturally and socially. Evolution and
134 RONALD DWORKIN, SOVEREIGN VIRTUES: A THEORY AND PRACTICE OF EQUALITY 448–49 (2000).
135 FRANCIS FUKUYAMA, OUR POSTHUMAN FUTURE 210 (2002).
136 JU¨RGEN HABERMAS, THE FUTURE OF HUMANNATURE 63 (2003).
137 Nick Bostrom & Rebecca Roache, Ethical Issues in Human Enhancement in NEW WAVES IN APPLIED ETHICS
120–52 (Jesper Ryberg,Thomas S. Petersen & ClarkWolf eds., 2008).
138 Julian Savulescu et al.,TheMoral Imperative to Continue Gene Editing Research on Human Embryos, 6 PROTEIN
& CELL 476–79 (2015).
139 Rule 28(b) EPC implementing Regulations; Article 6 (2) (b) Biotechnology Directive.
140 Recital 40 Biotechnology Directive.
141 Article 6 Biotechnology Directive and Article 53 (a) EPC.
142 Article 53 (a) EPC, Article 6 (1) and recital 14 Biotechnology Directive.
143 See above section 3.1.1
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epigenetics show that humannature is not a static biological reality, but rather it evolves
and is deeply influenced by environmental factors. For legal interpretation purposes, it
is notpossible to relyonabiological notionof ahumanbeing todistinguishnatural from
technological.The assertion that germline intervention is an offense to human dignity is
highly debatable when the aim is to protect future generations from severe incurable
diseases. The right to the highest attainable standard of health extends to preventive
medicine, while the right to education, and fruition of the results of science and tech-
nology, would further protect those wishing to change their physical, emotional, and
social human nature.
Another aspect to consider is that pursuant to the limitation imposed in Article 6 of
the Biotechnology Directive, any gene-editing activity that results in the destruction of
an embryo is not patentable. According to the CJEU, this limitation would even apply
if destruction occurred at an undetermined historical moment and does not form part
of the claimed invention, such as described in the claims.144 However, Recital 42 of the
Biotechnology Directive states that ‘such exclusion does not affect inventions for ther-
apeutic or diagnostic purposes which are applied to the human embryo and are useful
to it’. The CJEU, in Bru¨stle145 and ISCC,146 has provided a broad interpretation of the
legal concept of embryo.147 Intervention at the blastocyst stage is intervention in an em-
bryo. Any intervention could be considered medically useful to an embryo if it cures,
eliminates, prevents, or ameliorates a disease, impairment, or diminished capacity (in-
cluding pain, discomfort, and other symptoms).This entails that any intervention with
aminimummedical content or objective cannot be excluded from patentability for be-
ing offensive to human dignity.
Concerning the patentability of enhancement processes, under a strict literal inter-
pretation germline alteration is absolutely excluded, and genetic somatic intervention
is barred because it does not have a therapeutic purpose. However, arguably an inter-
vention may be useful to an embryo if it provides results that increase well-being and
life quality, even if these are generally understood as being beyond health.The language
chosen does not point to the concept of health but rather to the concept of usefulness.
A utilitarian vision of genetic intervention does point in a much broader direction than
linkage to strictly health-related issues. Delimitation of the legal concept of enhance-
ment in the sense of induced human evolution, as proposed, would be useful.148
Asmentioned above, theEPOhas accepted patents on gene editing.However, these
are still broad claims. Concerning specific uses, some jurisdictions will likely be more
inclined to accept patentability than others, eventually leading to divergent interpreta-
tions and a referral to the CJEU.
IV.C.b. Medical Methods: PersonalizedMedicine or Enhancement?
Previously, we considered whether gene-editing patent claims can be excluded on
morality and ‘ordre public’ grounds. Here we will address whether methods for gene
144 Nordberg &Minssen, supra note 18.
145 Case C-34/10, Oliver Bru¨stle v Greenpeace e.V, EU:C:2011:669.
146 Case C-364/13, International Stem Cell Corporation v Comptroller General of Patents, EU:C:2014:2451.
147 Nordberg &Minssen, supra note 18.
148 AnaNordberg,DefiningHuman Enhancement: Towards a Foundational Conceptual Tool for Enhancement Law,
25 J. L. INFO. & SCI. (2017).
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editing with health-related purposes can be patentable. Article 53 (c) EPC precludes
patentability ofmethods for treatment and diagnosticmethods.The rule only concerns
method claims: apparatus claims are not excluded,149 and product claims directed to
substances or compositions for use in methods are expressly accepted. These remain
patentable as long as the patentability requirements of novelty, inventive step, and in-
dustrial application are fulfilled.150 Patents may be granted for surgical, therapeutic,
or diagnostic instruments or any apparatus for use in such methods.151 Moreover, the
medical methods exception only prevents patentability of methods for (i) treatment of
the human or animal body by surgery, (ii) treatment of the human or animal body by
therapy, and (iii) diagnostic methods practiced on the human or animal body. Thera-
peutic methods to be applied either to plants, deceased bodies, or prosthetics not per-
manently attached to a body do not fall under this provision.152
A key element of this provision is whether the excluded methods are performed in
contact with the human body. In principle, gene-editing method claims will not be re-
fused as long as these are not performed in contact with the body. However, the mere
presence of a patient is enough to satisfy the criteria. A further cumulative requirement
for the exception to operate is that themethod is either amethod for diagnosis or treat-
ment or a method for surgery.
The concept of therapy is construed broadly. Methods are therapeutic if these cure
a disease or a malfunction of the human body, or have a prophylactic purpose.153 This
means any intervention is designed to cure, alleviate, remove, or lessen the symptoms
of, and prevent or reduce the possibility of, contracting any disorder ormalfunction,154
even if the symptoms are caused by natural circumstances, or are a response to environ-
mental conditions.155 A functional link or physical causality must exist between inter-
vention and a therapeutic effect produced on the body.156
Methods with dual use will be patentable, but only if claims are restricted to non-
therapeutic use and a clear distinction can be established between therapeutic and
non-therapeutic effects.157
Use of gene-editing technology to improve health and well-being is less controver-
sial than other uses of the technology. The rights to life and access to health care over-
ride some objections. However, as far as method claims are concerned, patentability
will be limited to non-therapeutic applications. Furthermore, allmethods of surgery are
149 T-712/93 Joint Medical Products/Ball and Socket Bearing for Artificial Joint [14.04.1997] unpublished.
150 Article 53 (c) EPC, last sentence.
151 See for all EPOGuidelines for examination, part C, ch. IV, 4.8.
152 T-24/91Thompson/Cornea [05.05.1994] OJ EPO 1995, 512.
153 G1/04 Diagnostic Methods [2006] OJEPO 334; T19/86 Duphar/Pigs II [1989] OJEPO 25; T290/86
ICI/Cleaning Plaque [1992] OJEPO 414; T438/91Meiji/Feeds [17.10.1994] unpublished.
154 T24/91Thompson/Cornea [1995] OJEPO 512.
155 T81/84 Rorer/Dysmenorrhea [1988] OJEPO 207, reasons 3; Cf. T385/09 Lely/Method of Cooling Animals
[25.11.2010] unpublished, reasons 3.6.
156 T329/94 Baxter/Blood Extraction Method [1998] OJEPO 241. See below the EPO board’s jurisprudence
concerning implants and prosthetic devices.
157 T144/83 Du Pont/Appe´tit Suppressant (n 4); T36/83 Roussel-Uclaf/Thenoyl Peroxide (n 4); T469/94
MIT/Perception of fatigue (n 13).CfrT116/85Wellcome/Pigs I (n 30);T780/89Bayer/Immunostimylant
[1993] OJEPO 440; T-438/91 Meiji/Feeds (n 9); T-290/86 ICI/Cleaning Plaque (n 4); T1077/93
L’Oreal/Protection Against UV Radiation (n 4; T-1635/09 Bayer/Composition for Contraception [2011]
OJEPO 542.
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excluded, regardless of their objective. This is because the determinant factor in char-
acterization as surgery is the health risk involved in a procedure (a substantial, non-
routine intervention on the human body requiring medical expertise) and not other
factors such as the purpose of the procedure or intensity of tissue perforation.158
Human rights-based legal thinking tends to frame the issue of gene editing in two
separate veins of reasoning: biosafety and prohibition of eugenics. In the abstract, it
is simple to weave out what is safe and presents a medical benefit from past horrific
experiments and eugenic doctrines. In reality, attempts to regulate gene editing face
the dual-use problem. Moreover, it is not straightforward to distinguish personalized
preventive medicine from human enhancement. In practice, concrete determination
depends on non-technical elements, such as social constructions of normality and hu-
man nature.159 As a result, emerging technology will pose considerable interpretative
difficulties to application of the medical methods patent exclusion.
IV.C.c. Patentability of Edited Plants
As indicated before, an increasingly important area of application for gene-editing tech-
nology is the agricultural sciences and plant sciences. Innovative plant breeding is not
only important for producingmore andbetter food for a rapidly increasing global popu-
lation by the construction of transgenic crop varieties engineered for resistance to spe-
cific diseases, but also for enhanced nutritional properties and other desirable traits.
Indeed, building upon rapid advances in synthetic biology and gene editing, modern
plant science is also becoming increasingly important in many other areas of industrial
applications, such as drug development, energy production, and space science.160 Such
inventions can be protected both by patents and by plant variety rights (PVR).161
Article 27(3)(b) of the TRIPS Agreement obliges countries to provide minimum
protection for plant varieties ‘either by patents or by an effective sui generis system or
by any combination thereof’.Moreover,WTOmembers have the choice to exclude ‘es-
sentially biological processes for the productionof plants’ frompatentability.162 Hence,
someSouthAmerican andEuropean countries alongwithChina and India take a highly
restrictive approach, excluding certain plant-related inventions from patentability.163
In contrast, the US Patent Act is (still) far more permissive and includes no explicit
statutory exemption of plant-related inventions. Not only can claims directed to plants
as such be protected but also plant parts, such as seeds and seedlings, and methods for
the production of plants, provided that all patentability requirements are met. The US
Supreme Court explicitly confirmed in J.E.M. Ag Supply v Pioneer Hi-Bred164 the long-
standing practice of the USPTO of granting utility patents on plants.165
158 G1/07 Enlarged Board of Appeal (EBA) inMedi-Psysics/Treatment by Surgery, order 1.
159 Generally see ANA NORDBERG, PATENTING NANOMEDICINE IN EUROPE: APPLYING THE ‘MEDICAL METHODS
EXCEPTION’ TO EMERGING TECHNOLOGIES (2017).
160 Minssen &Nordberg, supra note 18.
161 Sometime also referred to as breeders’ rights.
162 Cf. Standing Committee on the Law of Patents, 13th Session Geneva, Mar. 23 to 27, 2009 ‘Exclusions from
Patentable Subject Matter and Exceptions and Limitations to the Rights’, at59.
163 Minssen &Nordberg, supra note 18, at 81–98.
164 J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., 534 U.S. 124 (2001).
165 Franz-Josef Zimmer &Markus Grammel, Plant Patents in Europe, 34 BIOTECHNOL. L. REP. 121–31 (2015).
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Whereas national laws governing the patentability of plants may vary significantly
among countries, the need to protect the IP rights of plant breeders was acknowledged
by legislators as early as the 19th century.166 Today, PVR and patents form a synergis-
tic and complementary IP system.167 PVR protects new plants as a whole but cannot
protect single parts (eg a specific gene), while patents protect parts, but (in general)
not whole plants.168 The original intention was for patents and PVR to protect differ-
ent subject matter in ways appropriately adapted to the needs of different industries.
Until a few decades ago, plant breeding was conducted by traditional cross-breeding
methods based on empirical trial and error experimentation, and plant-related innova-
tionswere almost exclusively protectedbyPVR.Theproblem is, however, that the plant
industry has rapidly turned toward incorporating synthetic andmolecular breeding and
technically advanced selection systems.169 Today’s plant innovations are developed
using sophisticated science technology, including advanced gene-editing technology,
cell biology, genome and proteome research, genemapping, marker-assisted breeding,
and hybridization. The development of beneficial traits may thus be expensive, time
consuming, and risky.170
However, it is quite usual for breeders to enhance their ownbreeding lines by resort-
ing to beneficial traits from their competitors’ varieties, including commercially avail-
able protected plant varieties where previous gene editing cannot be traced back. This
stands in conflict with the interests of patent holders in the biotechnology industry,
and their own costly, risky, and time-consuming R&Defforts.171 As a consequence, the
distinction between PVR protection and patent protection has become blurred, with
some commentators warning that this ‘disrupts the equilibrium in the reward systems
of classical plant breeders and the biotech plant industry’.172
In Europe, this ‘disruption’ culminated with the EPO Enlarged Board of Appeal
(EBA) decisions on the consolidated referralsG2/12 (‘Tomato II’) andG2/13 (‘Broc-
coli II’). Considering the stipulations in Article 53 (b) EPC, the EBA affirmed that
products, namely plants or parts thereof, obtained by essentially biological processes
are in principle patentable under the EPC. This outcome leaves considerable leeway
for patenting novel and inventive plants and products thereof which have been pro-
duced by ‘conventional’ methods including breeding steps.The EBA also clarified that
this applies irrespective of whether such claims are formulated in product-by-process
formats or as per se products. Moreover, the combined effect of Broccoli/Tomato I &
II opens new opportunities for patenting GMOs. Although major industry players had
challenged the relevant patent claims, these were generally good news for innovative
plant breeders and agrochemical companies.173
166 Michael A. Kock & Christine Gould, Adapting IP to an Evolving Agricultural Innovation Landscape, 2 WIPO
MAGAZINE (2013).
167 Id.
168 Id.
169 Ylva Skoglo¨sa & Isabel Cantallops Fiol, Do Patents Get in the Way of Feeding the World?, MANAGING
INTELLECTUAL PROPERTY (2016), http://www.valea.eu/sites/www.valea.se/files/field page attachments/
54-59 valea europe16.pdf (last accessedMay 8, 2017).
170 Kock &Gould, supra note 166.
171 Skoglo¨sa & Fiol, supra note 169.
172 Id.
173 Minssen &Nordberg, supra note 18, at 81–98.
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These developments in European patent case law in recent years appear to have
widened the divide between breeders and the biotech industry. Under current EPO
case law, it appears possible that plant breeders are prevented from using genetically
manipulated variants to innovate their breeds without permission from patent hold-
ers. This decision has thus been perceived as favoring the big agrochemical corpora-
tions to the detriment of small plant breeders.174 The situation is complicated by the
fact that the national patent legislation of some European countries, such as Germany
andThe Netherlands, explicitly excludes from patentability products produced by es-
sentially biological processes, as well as the processes themselves. Consequently, two
European countries with a considerable bioagro industry are clearly not in line with the
EPO’s Broccoli II & Tomato II decisions and would probably not have granted those
patents.175 Potential litigation in these countries directed to corresponding or similar
types of patent might thus reach the CJEU.This court is not bound by the EBA’s deci-
sions and might interpret the Biotechnology Directive in line with German and Dutch
implementation. However, EBA decisions may have a more substantial impact at the
UPC, once it is finally up and running in Europe.176 On November 3, 2016, the Euro-
pean Commission adopted a notice on the interpretation of the Biotechnology Direc-
tive.177 Its view is that according to the intentions of the legislator, plants produced by
crossing and selection should not be patentable.The effect of the notice on the practice
of the EPO, and hence its value for legal interpretation purposes, including possible
follow-up measures, is currently under discussion between the EPO and its member
states. Faced with pressure from the EU, in December 2016, the EPO decided that ‘all
proceedings before EPO examining and opposition divisions in which the decision de-
pends entirely on the patentability of a plant or animal obtained by an essentially bio-
logical processwill be stayed ex officio’.178 Following internal debates, theEPOAdmin-
istrative Council decided to amend the relevant implementing regulations in order to
exclude from patentability plants and animals exclusively obtained by an essentially bi-
ological breeding process. The EPO’s proposal adopted by its Administrative Council
was intended to safeguard uniformity in harmonized European patent law and perhaps
anticipating the possibility and need for national courts to issue further referrals to the
CJEU and its potential for legal certainty disruption.The new provisions became appli-
cable with immediate effect starting on July 1, 2017.179
IV.C.d. Patent Wars: the Battle of Priority and the Battle of the Claims
The CRISPR/Cas9 patent war ignited in Europe with the filing of several oppositions
against what is considered to be the first patent granted in Europe for this technol-
ogy.180 The patent was granted by the EPO to the Broad Institute, MIT and Harvard
174 Skoglo¨sa & Fiol, supra note 169.
175 Id. See alsoMinssen &Nordberg, supra note 18, at 92–98.
176 Id.
177 CommissionNotice on certain articles ofDirective 98/44/ECof theEuropeanParliament andof theCouncil
on the legal protection of biotechnological inventions, C/2016/6997, OJ C 411, 8.11.2016, at 3–14.
178 Notice from the European Patent Office of Nov. 24, 2016 concerning the staying of proceedings due to the
CommissionNotice on certain articles ofDirective 98/44/ECof theEuropeanParliament andof theCouncil
of July 6, 1998 on the legal protection of biotechnological inventions, OJEPO 2016 A104.
179 Amended rule 27 b), EPC implementing regulations.
180 EP2771468, granted on Feb. 11, 2015.
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College on February 11, 2015, comprising a total of 53 product claims.181 It pertains to
research conducted by FengZhang and his research group (hereinafter,Zhang et al.). It
has been opposed by nine different entities.182 Opposition procedures could result in
several different outcomes ranging from amendment of claims to complete revocation
of the patent. In any event, it is likely that appeal(s) will be lodged.This can be a lengthy
procedure pending several years until a final decision is issued.
The patent landscape is vast and complex. The grant of the Zhang et al. patent was
closely followed by several divisional European patent applications. Some have been
granted,183 some are being opposedor arewithin the nine-month opposition period,184
while others are under examination.185 It seems predictable that some of these patents
will also be opposed by multiple parties. In the USA, the same patent family already
includes at least 13 patents, the first of which was granted on April 15, 2014.186 Several
further European and US pending applications are in this patent family.
A competing patent family directed toCRISPR/Cas9 currently includes aEuropean
patent application187 and a US patent application188 filed by the University of Califor-
nia, the University of Vienna, and Emmanuelle Charpentier. It covers research con-
ductedby JenniferDoudna andEmmanuelleCharpentier’s teams (hereinafter,Doudna
et al.). This patent claims a priority date of May 25, 2012, more than 6 months before
the priority date claimed in the Zhang et al. patent (December 12, 2012).
The subjectmatter of a patent applicationmust be novel and inventive over all public
disclosures made before the priority date. Generally, this also means that if the priority
date ofDoudna et al. is recognized and the corresponding patent granted/maintained,
the Zhang et al. patent will either be invalidated or remain dependable.
However, while the Doudna et al. patent claims an earlier priority date, none of
the applications were published until after the priority date claimed by the Zhang et
al. patents. In Europe, in light of the EPC, this means that the Doudna et al. disclo-
sure will only be relevant to the assessment of novelty, but not to the determination of
whether the Zhang et al. patents involve an inventive step. Considering that details of
the CRISPR/Cas9 systemwere published189 before the priority date of theZhang et al.
patents, in order for the claims of those patents to be patentable they must define sub-
ject matter that is novel and inventive over that publication. Opposition procedures
consider in this respect whether it would have been obvious, based on the disclosure
181 Id.
182 Communication of notices of opposition, Ref. TBI-2771468-OPP, Patent n. EP2771468, dated Dec. 22,
2015, https://register.epo.org/application?number=EP13818570&lng=en&tab=doclist (last visited May
5, 2017).
183 EP2784162, granted on Apr. 8, 2015. Also subject to oppositions.
184 EP2896 697, granted on Sept. 2, 2015; EP2940140; EP2921557; EP2848690; EP2825654.
185 A patent family search at the EPO lists a total of 194 entries globally. See European Patent Office,
Family list: EP2771468(A1) - 2014-09-03, http://worldwide.espacenet.com/publicationDetails/
inpadocPatentFamily?CC=EP&NR=2771468A1&KC=A1&FT=D&ND=3&date=20140903&DB=
worldwide.espacenet.com&locale=en EP (last accessedMay 24, 2017).
186 US 8 697 359, granted onApr. 2014 ‘CRISPR-Cas systems andmethods for altering expression of gene prod-
ucts’.
187 EuropeanPatentApp.No. 13793997 ‘Methods andcompositions forRNA-directed targetDNAmodification
and for RNA-directed modulation of transcription’.
188 US Patent App. No. 13/842859.
189 Jinek et al., supra note 22.
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presented by the Jinek et al. paper,190 that the CRISPR/Cas9 system would work in
vivo in eukaryotic cells.191
In theUSA, because theDoudna et al.patent applicationwas filedwith a priority date
of May 25, 2012—one day before the first-to-file rules in the America Inventor’s Act
came into effect—a patent interference proceeding was still possible. An interference
proceeding was initiated listing Doudna et al. as the senior party,192 leaving Zhang et al.
with the burden of proof. The interference declaration concerned all claims, and the
Patent Trial and Appeal Board concluded that the parties claim distinct subject matter,
and entered a ‘judgment of no interference-in-fact, which neither cancels nor finally
refuses either parties’ claims’.193
InEurope, inMarch2017 theEPOannounced its intention to grant the correspond-
ing Doudna et al. patent.194 The claims are quite broad and the patent is likely to be
opposed.
CRISPR/Cas9 has a complex and undefined patent landscape with possibly several
overlapping patent rights. It includes patents and patent applications covering the basic
CRISPR/Cas9 system andmethods for its use, but also new developments or improve-
ments (eg the new nuclease Cpf1,195 and specific applications for its use, eg claims for
therapeutic uses). In addition to the two competing research groups resulting in the
aforementioned patents, other parties are active with patents and patent applications
relevant to the technology. Given the number of research teams working in the area,
the complexity of the patent landscape is likely to increase with time and generate fur-
ther patent disputes. For example, the USPTO granted a patent that claims gene in-
activation by the use of chimeric restriction endonucleases. This was issued on Octo-
ber 4, 2016 with a priority date of February 3, 1999. The patent owners are the Pas-
teur Institute and the Boston Children’s Hospital, and the inventors Andre´ Choulika
and Richard Mulligan.196 Cellectis (the exclusive licensee) publicly announced ‘an
umbrella patent’ that ‘covers most of the gene-editing procedures done with a nu-
clease’, including those based on CRISPR/Cas9, TALENs, zinc fingers, and many
190 Id.
191 See James Legg, CRISPR/Cas Patent Wars Have Begun at the European Patent Office, BIONEWS
(2015), http://www.bionews.org.uk/page 589337.asp (last accessed Mar. 10, 2017); See also
Jacob Sherkow, CRISPR Dispute to Be Decided by Patent Office, MIT TECHNOL. REV. (2016),
http://www.technologyreview.com/view/545411/crispr-dispute-to-be-decided-by-patent-office (last
accessedMar. 10, 2017).
192 See Initial interference memo, Dec. 21, 2015.
193 Patent Interference No. 106,048, Judgment 37 C.F.R. § 41.127(a), Feb. 15, 2017.
194 EP2800811Methods andCompositions for RNA-DirectedTargetDNAModification and for RNA-DirectedMod-
ulation of Transcription. See also Sharon Begley,University of California’s CRISPR Patent Win in Europe Likely
to Be Challenged, https://www.statnews.com/2017/03/28/crispr-university-of-california-patent/ (last ac-
cessed Apr. 18, 2017).
195 Bernd Zetsche et al., Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System, 163 CELL
759–71 (2015).
196 U.S. patent 8,921,332 ‘Chromosomal modification involving the induction of double-stranded DNA cleav-
age and homologous recombination at the cleavage site’ issued on Dec. 30, 2014; and U.S. patent 9,458,439
‘Chromosomal modification involving the induction of double-stranded DNA cleavage and homologous re-
combination at the cleavage site’, issued on Oct. 4, 2016.
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meganucleases. Commentators have cast doubt on the patent’s validity and scope, an
indication that litigation might follow suit.197
TheCRISPR/Cas9 patent warswill likely continue over the coming years. Long and
complex proceedings, in both the USA and Europe, will unveil who owns the technol-
ogy and to what extent. Independently of the outcome in the priority battle(s), differ-
ent players will also seek to oppose and/or partially or totally invalidate specific claims.
Different grounds for invalidation are possible, including arguments concerning patent
exclusions under the EPC. The outcome of the battle of the claims has many variables
and is difficult to predict. In the meantime, while the actual ownership status over the
technology is undefined and despite ethical controversies, license agreements and joint
ventures with major industry partners have been announced. The industry is moving
toward future commercial applications, while the public debate on ownership and sci-
entific attribution is somehow overshadowing ethical and regulatory discussions.
In light of this uncertainty, it is not surprising that different forms of intervention
are currently being considered in Europe ranging from legislative changes in the EU
BiotechDirective, patent law, and procedure to the introduction of special compulsory
licensing regimes198 and creative user-generated and integrated solutions, such as the
development of industry wide e-licensing platforms.199
Whereas a detailed discussion of all possible forms of intervention falls outside the
scope of this paper, we will in the following elaborate on these types of solution that
seek to balance the application and governance of IPRs in relation to upstream and down-
stream technology.200
IV.C.e. Cross Licensing and Governance
Instead of seeking solutions bymodifying the legal framework, some authors have sug-
gested experimentingwith private orderingmechanisms generated by users (i.e. patent
pools, clearing houses, commons, open source)201 to respond to some of the IP-related
challenges in synthetic biology and gene editing explained above.These private order-
ing mechanisms operate within the current legal framework, appear mostly post-grant,
and are typically contract-based. They are presumably more appropriate than state-
enacted law because normally users would better understand the demands of the sector
and they would be able to respond more quickly to those demands without the delay
generally encountered in democratic decision-making processes.Moreover, these chal-
lenges are international in nature and, hence, any solutions should preferably be inter-
national as well. Nonetheless, international negotiations aimed at adoption of a new
197 See Jon Cohen, Dramatic Twists Could Upend Patent Battle Over CRISPR Genome-Editing Method, SCIENCE
(Oct. 5, 2016, Updated, 10/7/2016), doi:10.1126/science.aah7381.
198 See eg Final Report of the Expert Group on the development and implications of patent law in the field
of biotechnology and genetic engineering (E02973), published on May 17, 2016, http://ec.europa.eu/
DocsRoom/documents/18604/attachments/1/translations/ (last accessed Jan. 10, 2017) (recommending
that no further action be taken).
199 See eg Kock &Gould, supra note 166 (considering contract-based, user-generated solutions, and presenting
Syngenta’s TraitAbility e-licensing platform).
200 Nari Lee, Soili Nyste´n-Haarala & Laura Huhtilainen, Interfacing Intellectual Property Rights and Open Inno-
vation, SSRN ELECTRONIC J., http://ssrn.com/abstract=1674365 (last accessed May 8, 2017); Carl Mair,
Openness, Intellectual Property and Standardization in the European ICT Sector, 2 IPTHEORY 3 (2012);Michiel
Verlinden, TimoMinssen& IsabelleHuys, Reconciling IPRs andOpenness in Biobanking, 38EIPR 1–4 (2016).
201 THOMAS RIIS, USER GENERATED LAW (forthcoming).
Downloaded from https://academic.oup.com/jlb/article-abstract/5/1/35/4816224
by Danish National Library of Science and Medicine user
on 17 May 2018
72  Cutting edges and weaving threads in the gene editing ()evolution
treaty or treaty modifications tend to meet even more hurdles and delays than does
state-enacted law, rendering private orderingmechanisms an interesting channel for re-
sponding to speedy science-based developments in synthetic biology and gene editing.
In this light, the participants at a workshopwith experts and stakeholders inNovember
2013 in Copenhagen sponsored by the European Research Area Network in Synthetic
Biology (ERASynBio) recommended (amongst other things) to ‘[e]xplore opportu-
nities for private ordering mechanisms to improve transparency of ownership and to
facilitate licensing’.202 Additionally, other authors have signaled the relevance of such
models in synthetic biology and gene editing.203
Different types of private ordering mechanisms exist, ranging from IP sharing and
freedom to operate models, such as SYNGENTA’s e-licensing platforms204 or LEO
PHARMA’s open innovation platform205, to industry-wide licensing platforms.206This
positionmight also embrace the idea that upstream or basic technology should be kept
free of inhibiting IP, while downstream technology and products may be subject to IP.
This seems to be the approach of the BioBricks foundation, a key player in efforts to
create a freely accessible repository of standardized biological parts. The agreement
that governs the terms of contribution and use of BioBricks seeks to ensure that ba-
sic bioparts are not covered by IPRs or that the owner of IPRs agrees to non-assertion.
However, the agreement contains no clauses that prevent products that may be con-
structed from the combination and assembly of the parts from being patented or oth-
erwise protected by IP.207
With regard to gene-editing technology, patent pool or clearing house models (or
combinationsof the twomodels) couldbe especially helpful indealingwith IP fragmen-
tation. Inspiration for such approaches could be gathered from the ICT sector.Thiswas
demonstrated in December 2016, whenMPEG LA, one of the main operators of one-
stop licenses for standards and other technology platforms in consumer electronics,
announced that it has begun to examine the CRISPR-cas9 patent landscape to identify
essential patents that would need to be bundled together in licensing pools to enable a
202 TimoMinssen, Berthold Rutz & Esther van Zimmeren, Synthetic Biology and Intellectual Property Rights: Six
Recommendations—Reportfrom the IPExpertMeeting at theDanishAgency for Science, Technology& Innovation,
10 BIOTECHNOL. J. 236–41 (2015).
203 Arti Rai& JamesBoyle,Synthetic Biology:Caught betweenPropertyRights, the PublicDomain, and theCommons,
5 PLoSBIOL. e58 (2007); BertholdRutz, Synthetic Biology and Patents. A European Perspective, 10 EMBOREP.
S14–17 (2009).
204 The first initiative, the Syngenta e-licensing platform, TraitAbility, makes available some of the com-
pany’s most important native trait technology and a range of research tools for biotechnology, see
http://www3.syngenta.com/global/e-licensing/en/e-licensing/Pages/home.aspx (last accessed Jan. 10,
2016).
205 LEO Pharma Open Innovation is a collaborative space created to explore partnerships and collabo-
rate using disease-relevant in vitro assays as an initial stepping stone. The open innovation platform al-
lows insight and access to some unique research tools in order to test external compounds for disease-
relevant effects, but without the Partner having to disclose confidential information or giving up IP, see
http://openinnovation.leo-pharma.com/ (last accessed Feb. 15, 2016).
206 Kock &Gould, supra note 166.
207 Cf.TheBioBrickPublicAgreement (BPA), Biobricks Foundation, https://biobricks.org/bpa/ (last accessedFeb.
19, 2016).
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one-stop license ‘platform to reduce litigation risk and provide efficiency, transparency
and predictability to scientists and businesses worldwide.’208
IV.D. Legal SystemCoherence
There is a considerable legal theoretical, but also political, discussion concerning pol-
icy options between pluralism and harmonization.The discussion emerges concerning
every negotiation of an instrument of international law. Internally it is often present in
debates concerning the limits and boundaries of federal legislative powers, or central-
ization versus regionalisation. It is also particular visible in political debates concerning
plurinational integration projects such as the EU. Emerging technology, such as gene
editing, presents amultitudeof horizontal challenges across a varietyof legal disciplines.
It is also a technology which raises deep social and ethical questions and as such entails
possibilities for further legal and regulatory overlaps. As demonstrated in this section,
gene editing opens interpretative and even legislative challenges because often it is not
clear how these new technologic realities fit into legal categories, and operative con-
cepts of the applicable rules and regulations.209
The existence of a multi layered framework of laws and regulations is simultaneously
cause and consequence of a complex network of legal overlaps. Asmentioned above,
patentability exceptions or eligibility standards play a public policy role akin to tech-
nology regulatory norms. Although these are independent from technology regu-
lations, intersections should be considered and the need or not for coherence ad-
dressed, in particular, coherence between legal interpretation of patent exceptions
to gene-editing processes and the regulatory framework applicable to such interven-
tion. Because the regulatory framework might distinguish between different tech-
nological applications, interpreting eligibility rules as intended to deny incentives
to research that seeks to eradicate the transmission of severe hereditary diseases to
future generations is at odds with the function of the patent system. As a matter of
legal interpretation, it has to be investigated in light of the intention and purpose of
the patent systemwhether the legislator would have allowed for a broader patent el-
igibility approach if it had anticipated the technological possibilities for therapeutic
applications provided by gene-editing technology.
The issue of dual use is of particular importance to the concrete determination of
whether a technology should be excluded from public incentive mechanisms.210 Cer-
tain gene-editing intervention is or will be prohibited based on a number of reasons
(public health, precaution and safety concerns, or human dignity), while less contro-
versial applications might be allowed. However, patent protection is not necessarily
208 MPEG LA, MPEG LA Initiative to Address CRISPR Licensing, One-Stop Access Will Accelerate Ad-
vances in New Medicines, Organ Transplants and Agriculture (2016), http://www.businesswire.com/
news/home/20161206006182/en/MPEG-LA-Initiative-Address-CRISPR-Licensing (last accessed May
17, 2017).
209 See Ana Nordberg, Legal Method and Legal Interpretation in International IP Law: Pluralism or Systemic Co-
herence, in ATRIP CONGRESS 2016 PROCEEDINGS INTELLECTUAL PROPERTY AS FUNCTIONAL PLURALISM: THE
PARAMETERS, CHALLENGES AND OPPORTUNITIES OF VARIATION (Suzy Frankel ed., Edgar Elgar, forthcoming)
https://papers.ssrn.com/sol3/papers.cfm?abstract id=3035771.
210 See section 4.2.
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purpose-bound, so that only in certain claim types (eg secondary uses) would it be pos-
sible to differentiate. When a given invention can be developed in different directions,
it is excessive to deny patentability and thus incentives to innovation.
Moreover, legal coherence will imply that similar public policy considerations will
have to apply mutatis mutandis to other public forms of incentive, such as research
grants, prizes, and awards. Likewise, cross-licensemechanisms andcontractual arrange-
ments should equally be developed in light of general legal principles. Finally, gene
editing is simple to use in non-institutional contexts. Incentives to further research and
innovation are a powerful tool to stir technology in a socially responsible and safe di-
rection, but the nature of the technology implies the need for additional mechanisms
of governance such as exploring the possibilities for multilevel stakeholder dialog and
private society engagement.
Law, in its broader sense, is created, and developed in a given social context. Narra-
tives on science and technology play an interesting role ondefining howdifferent actors
will apply, interpret, and use their agency or discretionary powers. Court adjudication,
institutional practice by patent offices, decisions by ethical boards and regulatory ap-
proval authorities, negotiationof contractual arrangements andbusiness strategies, and
even individual decisions by private actors are not made in the vacuum, but rather in-
serted in a social context. In the next section, we address both the role and influence
of communication and public perception in legal debates concerning the regulation of
emerging technology, and on the other side the influence of litigation in the construc-
tion of such narratives.
V. COMMUNICATION AND PUBLIC PERCEPTION
The technological ability to alter genes has for a long time been a controversial issue
in public debate. In 1975, the Asilomar conference211 crystallized public attention on
the risks and merits of recombinant DNA technology, but controversies about genetic
inheritance go much further back (for instance around the use of eugenics). During
the 1970s and 1980s, however, controversies over the use of genetic modification in
agriculture and human and animal reproduction regularly surfaced in many countries
around the world. In the 1990s, these debates reached unprecedented public attention
with the decision tomixGMOandnon-GMOsoybeans inAmerican exports to Europe
in 1996, and the birth of the cloned sheep Dolly in 1997.These developments resulted
in what has been called a ‘global controversy on biotechnology’.212
In many ways, current public debate about gene editing is therefore building on, or
reviving, controversies and arguments which are already deeply entrenched in many
societies. At the same time, the tendency is to present the issues as revolutionary and
as if this specific point in time is more crucial than any other. This was also the case
when theUSNational Academyof Science, theUSNational AcademyofMedicine, the
Royal Society, and the Chinese Academy of Sciences hosted an international summit
on Gene Editing in Washington, in December 2015 (the organizers later referring to
211 Priska Gisler &Monika Kurath, Paradise Lost? ‘Science’ and ‘the Public’ after Asilomar, 36 SCIENCE TECHNOL.
&HUM. VALUES 213–43 (2011).
212 MARTIN BAUER &GEORGE GASKELL, BIOTECHNOLOGY: THE MAKING OF A GLOBAL CONTROVERSY (2002).
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this as theHumanGeneEditing Initiative (HGEI)213).TheChairmanof the organizing
committee, David Baltimore, laid it out in the introduction:
Today, we sense that we are close to being able to alter human heredity. Now we must
face the questions that arise. How, if at all, do we as a society want to use this capability?
This is the question that has motivated this meeting.214
What such statements make clear is that more is at stake than simply a technology or
a technological platform. It is about how society develops and how various groups of
stakeholders, governments, and publics try to direct this development. Such an under-
standing of controversies as deep-founded disagreements about values is also in line
withmuchof the scholarly researchonpublic controversies about biotechnologywhich
have been published during recent decades.215 That research forms the background for
this section.
One of the crucial points of discussion at the 1975Asilomar conferencewaswhether
science’s system of self-regulation is trustworthy and robust, or whether it is necessary
to enforce regulation from the outside. Several decades later, when the debate about
GMO had developed into a full-scale global controversy, this was still a key issue for
publics around the world: Can we trust science to govern its own development in a
socially acceptable way? In a seminal analysis of the use of biotechnology in the health
care system, Michael Mulkay has shown that most of the argumentation on either side
of the controversy springs from a basic assessment of the role of science in society.
That is to say,while proponents see science as apositive force in society,whichbrings
about solutions to problems, and present this worldview in a rhetoric of hope, oppo-
nents understand science tobe a social phenomenonwhich createsmoreproblems than
it solves and present this worldview in a rhetoric of fear. Interestingly, both sets of ar-
guments present technoscientific solutions as revolutionary and as having far-reaching
consequences. In this context, the important point is that any new technoscientific de-
velopment will be seen in light of previous controversies.
When public communicators (for instance journalists and opinion makers) make
sense of a new phenomenon, they will invariantly draw a comparison with known ex-
amples and use these frames of reference to make sense of new developments by pre-
senting them in well-known storylines. What this part of history also reminds us is that
the call for a moratorium on human germline editing by the Washington meeting in
2015 has a clear precedent in the 1975 Asilomar conference—a call, however, whose
current efficacy can be very hard to evaluate. While its regulatory impact is probably
quite small—as dealt with elsewhere in this paper—its public value in terms of gener-
ating legitimacy might be more important. By calling for a moratorium on the use of
certain aspects of CRISPR/Cas9 technology, other aspects of use can simultaneously
be treated as legitimate and justified.
213 See The National Academies of Sciences Engineering Medicine, Human Gene-Editing Initiative (2017),
http://www.nationalacademies.org/gene-editing/index.htm (last accessedMar. 3, 2017).
214 International Summit on Human Gene Editing: A Global Discussion (2017), http://www.nap.edu/21913 (last
accessedMay 17, 2017).
215 In 1992, the journal ‘Public Understanding of Science’ was started and has since been one of the hotspots
of research on public controversies over science, but there are a number of earlier studies, see eg DOROTHY
NELKIN, CONTROVERSY: POLITICS OF TECHNICAL DECISIONS (1st ed., 1979).
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V.A. Science and Society
After theWashingtonmeeting, theHGEI commissioned a ‘consensus study’ of ‘the sci-
entificunderpinningsof humangene-editing technology, its potential use inbiomedical
research and medicine—including human germline editing—and the clinical, ethical,
legal, and social implications of their use’.216 The aim of this study was formulated by
the actors behind the HGEI in a concluding statement after the original Washington
Meeting: ‘The forumwillmobilize the global expertisenecessary tohelp societydevelop
norms for acceptable uses of human gene-editing technology.This is an important mo-
ment in human history and we have a responsibility to provide all sections of society
with an informed basis for making decisions about this technology, especially for uses
that would affect generations to come’.217
While this is certainly a noble ambition, social scientific research into public contro-
versies about emerging technology suggests that such an approach might not be suc-
cessful. It might not be so easy to ‘help society develop norms for acceptable uses’, just
as the idea of ‘providing society with an informed basis for decision-making’ is in dan-
ger of misinterpreting the fundamental drivers of the controversy. In this context, we
will just mention two reasons for this.
First, science and society should not be regarded as two distinct spheres, such that
science can be developed independently of social, ethical, and legal reflection and only
subsequently be made the object of societal decision-making. Rather, science is part of
society, and social sense-making about it is a continuous process. It is therefore utterly
problematic to first do the science and subsequently agree on the norms for its uses.
Science does not take place in a vacuum, but in a society in which a myriad of actors
have interests and want to influence or oversee its activities, applications, and implica-
tions. One good example of this can be found in the pre-history of CRISPR/Cas9 tech-
nology. Interestingly, the experimental evidence for theCRISPR/Cas9 systemwas first
obtained at the sugar and food ingredients companyDanisco.218 During the 1980s, they
also developed sugar beet resistant to glyphosate through the use of genetic engineer-
ing. In an effort to take into consideration the criticism of using antibiotic resistance
genes as a selectionmarker, a new selection system based on sugarmannose was imple-
mented.These innovationswere, however, never commercialized byDaniscodue to en-
vironmental concerns. In light of general European skepticism toward the use ofGMOs
in agriculture,Danisco decided to discontinue its R&D activities in this area.This story
demonstrates how a corporation tried be responsive to public concerns (over the use of
antibiotic resistance genes), but ended up halting its otherwise promising path of tech-
nology development because of concerns over public skepticism toward GMO crops.
Daniscowas not the only European company to put a halt to agricultural biotechnology
around the turn of the century. Indeed, in many ways public skepticism toward GMO
has become a seminal lesson about the need to take public concerns seriously in order
216 The National Academies of Sciences Engineering Medicine, Human Gene-editing Initiative,
http://www.nationalacademies.org/gene-editing/consensus-study/index.htm (last accessed Mar. 3,
2017).
217 International Summit on Human Gene Editing: A Global Discussion, supra note 214.
218 Researchers at the company discovered that the thermophilic Gram-positive bacterium Streptococcus ther-
mophilus was resistant to virus attack when harbouring the CRISPR/Ca9s system and that the specificity of
the resistance was determined by the variable spacer sequences of the CRISPR locus and their sequence ho-
mology to the protospacer sequence in the viral genome.
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to avoid them later on preventing technological development.219 Avoiding the GMO
trap is seen to be paramount.220
While it is certainly important to provide material that will help societal actors deal
with the social, ethical, economic, technical, and political challenges posed by the de-
velopment of gene-editing technology, it is not plausible to imagine an orderly linear
process of information gathering, development of norms, decisions about acceptable
applications, and subsequent dissemination of technology. Rather, these things hap-
pen at the same time and in many conflicting and interrelated processes. Just to men-
tion one example, the patent dispute demonstrates how economic expectations are al-
ready enormously important in shaping the framework for gene-editing technology. In
such situations, all communication about the technology can be seen to be directed by
vested interests. One clearcut example of this is the January 2017 piece by the Direc-
tor of the Broad Institute, Eric S Lander, in Cell, entitled ‘The Heroes of CRISPR’.221
This piece was heavily criticized for demonstrating typical sexism in science by down-
playing the role of female scientists Jennifer Doudna and Emmanuelle Charpentier with
obvious links to the story of Rosalind Franklin and the Nobel prize for the discovery
of DNA. However, such story writing has also undoubted importance in terms of in-
fluencing public perceptions of the ongoing patent trial. If Lander had been successful
in describing Doudna and Charpentier as only some among several scientists working
with CRISPR, and portraying Zhang as the central hero, he would have strengthened
the claims by Zhang and therewith those of the Broad Institute. As it happens, however,
the social media storm that arose around Lander’s article might well have had adverse
effects on their cause.The point here is that science is not separate from the rest of soci-
ety but intermingledwithmanydifferent parts of society and amyriad of actorswill take
an interest in what happens within science. Communication about science is therefore
not something that can happen ‘after the fact’ of its development.222 Rather, commu-
nication forms part of making scientific and technological development happen.
Second, and linked to the first aspect, we need to be aware of the fundamental unease
in the relationship between science and democracy in our democratic societies. On the
one hand, science, as any other aspect of society, should be democratically accountable.
On the other hand, however, this accountability challenges the epistemic authority of
science and its accountability toward truth. Philosophy of science has produced a num-
ber of suggestions for how to deal with this challenge, but the basic tension remains:
Can we democratically decide on what should count as truth in society? The idea of a
‘consensus study’ as formulated by the HGEI builds on the idea that a group can iden-
tify the areas and arguments uponwhich there is consensus—which suggests that truth
and democratic decision-making are aligned, thereby circumventing potential tensions
between science and politics. However, the HGEI followed up by suggesting that all
aspects of society should be provided with an ‘informed basis for making decisions’,
219 Elise McCarthy & Christopher Kelty, Responsibility and Nanotechnology, 40 SOC. STUD. SCI. 405–32 (2010);
Nick Pidgeon & Tee Rogers-Hayden, Opening Up Nanotechnology Dialogue with the Publics: Risk Communi-
cation or ‘Upstream Engagement’?, 9 HEALTH RISK & SOC. 191-210 (2007).
220 Arie Rip, FolkTheories of Nanotechnologists, 15 SCI. CULTURE 349–65 (2006).
221 Eric S. Lander,TheHeroes of CRISPR, 164 CELL 18–28 (2016).
222 Ursula Plesner & Maja Horst, Before Stabilization: Understanding the Communicative Aspect of Non-
standardization of 3D Digital Models in the Building Industry, 16 INFO. COMM. & SOC. 1115–38 (2017).
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thereby bringing those tensions back into play. During the first decades of controversy
over biotechnology, the most common explanation of opponents’ skepticism was that
they lacked information or knowledge about the technology—and as soon as they be-
came informed they would cease to be skeptical. An overwhelming number of stud-
ies have demonstrated that this explanation is too simplistic and/or simply wrong.223
Many skeptics are well informed about the technology in question, but evaluate and
value specific facts, risks, and insecurities differently from supporters of the same tech-
nology. Similarly, the notion of an ‘informed basis for making decisions’ needs to be
unpacked, so that it takes into account that the question of what counts as knowledge
and information is often a controversial issue in itself.224
V.B. Public Trust
Asmentioned above, a fundamental aspect of controversy about biotechnology can be
understood as a question of whether actors see science as a solution to problems in so-
ciety or whether science is seen as something that creates problems. At the core of this
discussion lies the issue of trust (linked to questions of control, blame, and social in-
tegration, but for reasons of simplicity we focus on trust here225). If people are to be
convinced by arguments built on information and knowledge, they have to trust the
credibility and ethos of the speaker. A fundamental problem for proponents of gene
editing is therefore to establish science as a credible source of true and/or useful knowl-
edge and beneficial technology. As long as large parts of societies do not believe that
technoscientific development can be trusted to be in the interest of improving
society—including those disbelievers—then skepticism toward the technology will
prevail. Rather than talking about establishing an informed basis for decision mak-
ing, the main focus should therefore be on establishing trust.226 However, in this re-
gard, patent trials risk making this effort much harder. Studies of public trust in science
demonstrate that whilemany people are sympathetic to the idea of science in itself—as
an activity for establishing true knowledge—they become deeply skeptical when sci-
ence is seen to be in cahootswithmarket forces andmultinational companies.227 Patent
litigation that drags out for years will therefore in itself most likely contribute to skep-
ticism because it suggests that scientists and scientific organizations are really ‘in it for
the money’ rather than being concerned about truth and improving people’s lives.
Despite these complexities, we do not mean to suggest that the HGEI has no merit.
The crucial question is what our expectations toward public discussion of this technol-
ogy should be. Public engagement and deliberation is not likely to produce final so-
lutions to controversy about biotechnology. However, this does not mean public dis-
cussion is futile—rather, it suggests the opposite. Since public discussion concerns the
role of science in shaping future society, it amounts to some of the most important
223 MARTINW BAUER, ATOMS, BYTES AND GENES (2015).
224 ALAN IRWIN & BRIANWYNNE, MISUNDERSTANDING SCIENCE? (1996).
225 Maja Horst,Collective Closure?: Public Debate as the Solution to Controversies about Science and Technology, 53
ACTA SOCIOL. 195–211 (2010); MARY DOUGLAS, RISK AND BLAME—ESSAYS IN CULTURAL THEORY (1996).
226 Rick E. Borchelt&KristianH.Nielsen,Public Relations in Science:Managing the Trust Portfolio, in ROUTLEDGE
HANDBOOKOFPUBLICCOMMUNICATIONOFSCIENCEANDTECHNOLOGY 58–69 (MassimianoBucchi&Brian
Trench eds. 2014).
227 Torben Hviid Nielsen, Public Perception: Behind the Color Code of ‘No’, 15 NAT. BIOTECHNOL. 1320–21
(1997).
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political discussion for the future knowledge society. Public discussion offers a possi-
bility of placing science right at the heart of political decision-making in society, and
makes crystal clear that the key issue is about trust. However, we need to avoid look-
ing at current skepticism toward gene editing228 as a nuisance or as a roadblock to be
cleared as fast as possible. Rather, it is an opportunity for amuchmore fundamental dis-
cussion of the role of science in society and for establishing a better and more trustful
relationshipbetween science andotherparts of society.While this approach is notmade
easier by the patent disputes over CRISPR/cas9, scientists and other actors who want
to support technoscientific progress in society have to find ways of engaging in fruitful
dialog anddiscussionwith the rest of society. Such engagement should not be restricted
to technical aspects of gene editing, but has to encompass the overall role of science in
society, and the use and merits of scientific methods in a way which includes actors,
rather than leaving them outside or—even worse—disenfranchised or alienated. The
fact that science ultimately has to be democratically accountable does not mean that
scientists have to simply succumb to whatever is democratically decided in society, but
that they have a duty and an obligation to participate in democratic decision-making
and tomake sure that the resulting technoscience is evaluated as democratically robust
and acceptable. This work is importantly not about selling science to the public, but
about a lively democratic discussion, in which all parties enlighten themselves and each
other about how to create a robust knowledge society.
VI. A WAY FORWARD
The broad implications of gene-editing technology and the wide spectrum of potential
misuses have to be clearly addressed. Simultaneously, science and scientific freedom is
an essential human value that must be preserved and defended. In that regard, it can be
assumed that blanket banson someapplicationsof gene editing are inefficient if they are
not internationally enforceable.Theoretical researchwill proceed and experimentation
is likely to relocate to more permissive jurisdictions.229 Moreover, the danger is that
moratoria will merely postpone the problem until an actor with overwhelming market
power steps in, sweeping aside regulatory approaches and flipping the power balance
by building and using market demand to pressure for favorable regulations.
This means that upfront embedding of ethical, legal, and communication consider-
ations in bioscience research is necessary. Freedom to pursue new avenues to advance
knowledge and technical possibilities should entail special attention to risk assessment,
prevention, and management. Funding for these areas should be a top priority in the
gene-editing area.
A Bio-Law framework is already established in International, European, and Na-
tional legislation. This framework is based on a notion of human genes as human-
ity’s common heritage. However, this legal concept and its linkage with human dignity
should not be interpreted literally. International texts clearly defend diversity and state
228 Cary Funk, Brian Kennedy B & Elizabeth P. Sciupac, U.S. Public Opinion on the Future Use of Gene
Editing, U.S. PUBLIC WARY OF BIOMEDICAL TECHNOLOGIES TO ‘ENHANCE HUMAN ABILITIES (2016),
http://www.pewinternet.org/2016/07/26/u-s-public-opinion-on-the-future-use-of-gene-editing/ (last ac-
cessed Sept. 24, 2016).
229 Katrine S Bosley et al.,CRISPRGermline Engineering—TheCommunity Speaks, 33NAT. BIOTECHNOL. 478–86
(2015).
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that heritable genetics are only a part of what human beings are, as social and cultural
elements are also of fundamental importance.These texts also recognize that epigenetic
effects are important and that thehuman species has not ceased to evolve. In the context
of gene editing, human dignity should not be understood as equivalent to preserving a
legal fiction of static biological identity. A more useful framework will focus on draw-
ing balanced boundaries and establishing guidelines for the exercise of autonomous in-
formed personal choices vis a` vis their wider social implications.
Concerning innovations in plants and animals, a regulatory framework for emerging
science and technology should take into consideration the broader picture of the global
challenges that humanity is facing, such as the responsibility of humanity to maintain
and preserve the biosphere and biodiversity, and counteract the effects of human inter-
vention (such as global warming)which in turn are alsomentioned in the human rights
framework.
Law and regulations should address ethical considerations. In this sense, we con-
clude that reasonable precautionwill remain necessary to address uncertainties but that
it should not unnecessarily hold back science. Normative choices should not be pris-
oners of scientific unknowns. Safety issues of emerging technology for intervention in
the human body can be tackled similarly to other health and wellness technology. In-
dividual (and collective) risk versus benefit assessment should guide and underline au-
tonomous and informed decisions. General safety rules concerning testing on human
subjects, clinical use of experimental procedures, clinical trials, product safety, and en-
vironmental protection can adapt to technological progress. In sum, we submit that
regulations should be imbuedwith flexibility while preserving their preventive and pre-
cautionary function.
In addition, ethical evaluations of emerging technology, such as gene editing, will
increasingly have to address ‘dual-use’ dilemmas. Gene-editing technology will have
a vast number of distinct possible applications, some more controversial than others.
Blanket prohibitions and moratoria do not serve the best interests of society. At the
current stage, the preferable route rests in specific ethical evaluation at each stage of re-
search and technology use, accompanied by upfront embedding of dedicated research
into the ethical, legal, and social implications of the underlying bioscience research.
Although patent law function ismostly anchored in utilitarian arguments, in Europe
rules on patentable subject matter and exceptions from patentability assume a de facto
public policy role and can be described has entailing regulatory effects. Construction
of such norms through judicial adjudication reveals a need for a stronger interface be-
tween legal arguments, scientific state of the art, and ethical and social considerations.
With regard to intellectual property rights, we believe that the traditional structure
for incentivizing technological progress should be neither disregarded nor overused.
Improvements in patent examination procedures will bring clarity and avoid upstream
litigation. Pre-grantmechanisms can restrict incentives for technology deemed unethi-
cal, or lacking novelty or inventiveness. Further clarification on the functioning and ap-
plication of the research exemption and strengthening user-generated solutions at the
post-grant level will mitigate typical limitations on research imposed by patent rights.
Given the extremely complex and dense IP landscape in gene editing, it will be partic-
ularly important to explore novel ways for governing, managing, and sharing protected
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technology through clearing houses and patent pools. MPEG LA’s recent initiative to
address CRISPR licensing provides an interesting example of such approaches.230
Emerging technology in life science generally creates heated and emotionally
charged debate. In a democratic society, the task of creating new regulations and/or
applying existing frameworks to such new technology is not, and should not be, im-
mune to social debate. However, public debate often falls prey to myths and misinfor-
mation. In this context, scientific communication should claim a prominent role. Re-
garding the communication-related aspects of gene editing, wewould like to stress that
scientific communication should reflect the role of science in society and its essential
role for humanity and civilization. Past atrocities should serve as a permanent warning
of what must never be repeated. However, this should not cast the shadow of distrust
over science.While transparency and accuracy should guide scientific communication,
global-scale responsibility and governance should be fostered by and for every stake-
holder. A positive stance toward scientific development should guide interdisciplinary
dialog. In that respect, we are convinced that interdisciplinary thinking is crucial and
should increasingly form part of future legislative initiatives and other types of legal de-
velopment. Stakeholders andpublic engagement indebate are alsonecessary inorder to
create a base for legitimacy. And in order to contribute to that way forward, we suggest
five general guidelines for each actor’s engagement in public discussion of gene-editing
technology, as well as for broader discussion of technoscientific development:
First, we believe that communication should focus on building trust and long-term
credibility.This can only be achieved when all actors feel that they are respected as val-
ued members of society. It is crucial to address concerns openly and take them seri-
ously. In a world of disinformation, all arguments, no matter how irrational or emo-
tional, should be answered with facts or other forms of reasoned argumentation.
Second, scientists need tobecomemoreproactive and visible in communicating their
research, since trust has to be built through direct relationships with other actors. Pro-
fessional communicators are important, but communication cannot be left entirely to
marketers and public relations professionals.
Third, communication and public engagement should form an ongoing aspect of
technoscientific development, rather than an add-on once some technology is fully de-
veloped. Constructive criticism is a resource for development of robust technology. At
the same time, ongoingdiscussionof possibilities, opportunities, and risks also serves to
develop, strengthen, and nuance the ability of various publics to understand the com-
plexities of emerging technology.
Fourth, the scientific-technological community should engage in a concerted effort
in seeking to prevent public science communication from being taken over and steered
by the disputes and arguments of the interested parties in intellectual property litiga-
tion. Put differently, toomany IP tactical considerations influencing howpublic science
is communicated might result in erosion of general trust in science as an activity with
beneficent societal goals.
Finally, normative decisions should, to the greatest possible extent, be based on the
state of the art in the sciences (natural and social), ethics, and legal scholarship.This is
a complex task, not only due to rapid scientific developments, but also because, since
230 See supra note 208.
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gene editing is a global challenge, solutions need—as far as possible—to be debated
and established at a global level.
Negotiation of international treaties and enactment of derivative international legis-
lation is a complex, lengthy process. Simultaneously, supranational entities face grow-
ing criticism over lack of transparency, lack of accountability, and democratic deficit.
Reception and implementation of international instruments faces considerable hurdles
resulting in lack of harmonization or deficient implementation. Furthering multi-actor
dialog, such aswepropose,would also likely result in an improvement inongoing efforts
to develop legitimacy and ensure enhanced compliance with international legislation.
Because international negotiations take time and are often linked with complex in-
ternational relations strategies andpower balances, harmonization throughparallel leg-
islative national development is often the only time-efficient solution. In this context, a
broader and inclusive debate can bring forth a wider range of informed arguments and
achieve at least aminimumdegreeof international consensus. In light of slow regulatory
response, informal and soft lawmechanisms can play an important role in achieving an
alternative route to regulation, an example are emerging initiatives, debates and calls
for major right holders to commit to ethical licensing.231 In this sense, corporate social
responsibility could also benefit if the major actors adopt a cross-disciplinary embed-
ding in their research and development and a multilevel framework for dialog in their
internal decision making. Furthermore, research funding bodies should consider pay-
ing closer attention to IP questions, namely addressing the responsibilities of surrogate
licensing entities.
VII. CONCLUDING REMARKS
In this paper, we have argued that the complex issues of regulating emerging technol-
ogy require an interdisciplinary dialog that should be based onmulti-actor approaches.
The need for these approaches became particularly evident in our analysis of ground-
breaking developments stimulated by gene-editing technology.These raise a variety of
pressing scientific, legal, ethical, and societal issues, ranging from regulation of science
and protection of inventions to crucial ethical issues and narratives of public percep-
tions.
The debate is far too important and pervasive to be paralysed by disciplinary feuds
and lack of communication.The exceptional nature of the technology and its unprece-
dented potential presents not only great challenges but also the rare opportunity to
develop suitable lines of jurisprudence and adapt laws and regulations. We regard the
interdisciplinary approach here proposed as a tool to face known risks and uncertain-
ties, and ensure that the law is neither left lagging behind technological development
nor caught up in rhetorical traps. Given the rapid speed of technological developments,
the risk arises that overstrict legal and regulatory frameworks result in a straitjacket that
could limit technological development. Definitional issues and user-generated solu-
tions pose a particular challenge, not only as a matter of legal interpretation but also
as a broader communicational concern. Since the progress of science regularly out-
paces legislative creation and judicial adjudication, legal definitions can easily become
outdated and hamper innovation. Their enactment must be fully informed and their
231 Jacob S. Sherkow, Patent Protection for CRISPR: An ELSI Review, 43 J. L. & BIOSCI. 565, at 571 (2017).
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usefulness carefully considered. In areas as dynamic as life sciences, inclusion of dy-
namic interdisciplinary elements should complement literal and historical elements in
traditional legal interpretation.This must be balanced by the need for a certain degree
of legal certainty, which will remain important for most stakeholders.
While this paper presents a selection of regulatory issues that we regard as particu-
larly relevant, including the important regulatory effect of patent rules, it is also impor-
tant to recall that thesemerely represent the tip of the iceberg. Law is a complex system
of norms, additional regulatory frameworks, and other IP rights, such as copyright, data
protection, regulatory exclusivities, and trade secrets, which have an increasing impact
on innovation in the life sciences. Increasing intersections and overlaps between these
laws, rights, and regulations have to be factored into legal analysis through application
of a systemic perspective. It also became clear that in order to achieve well-balanced
and feasible solutions, it will be absolutely mandatory to carefully distinguish between
the great variety of techniques used in gene editing and the completely different areas
of applications.
Against this background, we believe that broader societal involvement, public com-
munication, dialog between sciences, interdisciplinarity, and proactive legal thinking
and use of contextual interdisciplinary elements in legal interpretation and legislative
activity have become more important than ever. It is essential to take a positive stance
toward science and technology, a stance that allows us to reap the benefits while solidly
anchoring research and market practices in the fundamental values of humanity. The
regulatory framework needs to be further developed so as to effectively channel the
power of technology and direct it to beneficial applications. Humanity should be kept
in the driving seat, rather than being trampled by technology.
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